INTRODUCTION {#s1}
============

Peritoneal carcinomatosis (PC), as a lethal regional progression for patients with colorectal cancer (CRC), has long been considered as a terminal condition with few effective treatments. In the past, the median overall survival (OS) of PC from colorectal cancer is 4 to 7 months after palliative surgery or 5-FU-based systemic chemotherapy with best supportive care \[[@R1]-[@R3]\]. Current systemic chemotherapy focusing on new chemotherapeutic agents such as oxaliplatin and irinotecan, along with anti-angiogenesis molecular targeting agents cetuximab and bevacizumab \[[@R4]-[@R7]\], could extend the median OS up to about 12 months \[[@R5]\]. However, long-term survival is still hard to be achieved by systemic chemotherapy alone.

Researches on treatment of CRC PC did not reveal promising progress until the development of a comprehensive treatment strategy including cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and perioperative chemotherapy.\[[@R8]-[@R15]\] This new comprehensive treatment improves the median OS of selected patients with CRC PC up to 21-63 months, and 5-year survival rate up to approximately 40% \[[@R16]-[@R28]\], or even 58% according to the American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution study \[[@R29]\]. It has been widely recognized in North America, Europe, Australia, and Japan \[[@R14], [@R24], [@R26], [@R30]-[@R32]\]. In the 9th International Congress on Peritoneal Surface Malignancies in Amsterdam in 2014, peritoneal surface oncology group international (PSOGI) reached a consensus that CRS+HIPEC should be considered as the standard therapy for the selected patients with mild-to-moderate CRC PC \[[@R33]\].

Nevertheless, therapeutic efficacy of this comprehensive treatment strategy for CRC PC patient remains controversial due to insufficient convincing evidence. Therefore, we conducted this meta-analysis of published clinical studies to verify the efficacy of this strategy against CRC PC.

RESULTS {#s2}
=======

Basic characteristics of all data {#s2_1}
---------------------------------

### Results of literature search {#s2_1_1}

Literature search identified 326 researches, 76 of which met the inclusion criteria, including 1 randomized controlled trail (RCT) (87 patients) \[[@R12]\], 14 non-randomized controlled studies (3,092 patients) \[[@R13]-[@R15], [@R26], [@R28], [@R29], [@R34]-[@R40], [@R99]\], and 61 non-controlled studies (6,857 patients) \[[@R16], [@R19]-[@R21], [@R41]-[@R92], [@R100]-[@R104]\]. The other 250 studies were excluded for miscellaneous reasons, and the flowchart of search strategy is showed in Figure [1](#F1){ref-type="fig"}. We conducted a meta-analysis on the 15 controlled studies (3,179 patients) and a summary of 76 HIPEC-related studies (10,036 patients).

![Study flowchart of systematic reviews and meta-analyses](oncotarget-08-55657-g001){#F1}

### Study characteristics {#s2_1_2}

The characteristics of 15 controlled studies \[[@R8]-[@R15], [@R26], [@R28], [@R29], [@R34]-[@R40], [@R99]\] were shown in Table [1](#T1){ref-type="table"}-[5](#T5){ref-type="table"}, and all 76 selected studies \[[@R12]-[@R16], [@R19]-[@R21], [@R26], [@R28], [@R29], [@R34]-[@R92], [@R99]-[@R104]\] were summarized in Table [6](#T6){ref-type="table"}-[10](#T10){ref-type="table"}. All these studies were published between 1993 and 2016 as full texts, performed in 19 countries and regions (Table [11](#T11){ref-type="table"}-[19](#T19){ref-type="table"}). Fifty-eight studies were single-center studies \[[@R12], [@R16], [@R19], [@R21], [@R35], [@R36], [@R38]-[@R43], [@R45], [@R43]-[@R53], [@R55]-[@R57], [@R60]-[@R63], [@R66]-[@R71], [@R74]-[@R83], [@R86]-[@R92], [@R99], [@R100], [@R102]-[@R104]\], and the other 18 were multicenter studies (participating institutions from 2 to 28) \[[@R13]-[@R15], [@R28], [@R29], [@R34], [@R37], [@R44], [@R46], [@R54], [@R58], [@R59], [@R64], [@R65], [@R72], [@R73], [@R84], [@R85], [@R101]\]. In these multicenter studies, 6 studies were performed by over 10 participating institutions included studies conducted by Glehen et al (*n* = 28, a central database) \[[@R13]\], Glehen et al (*n* = 25, a central database) \[[@R54]\], Elias et al (*n* = 25, a central database) \[[@R14]\], Esquivel et al (*n* = 21, The American Society of Peritoneal Surface Malignancies (ASPSM)) \[[@R29]\], and Prada-Villaverde et al (*n* = 15) \[[@R72]\]. A total of 63 articles were retrospective studies, in which 11 articles were included in this meta-analysis \[[@R13]-[@R16], [@R19]-[@R21], [@R28], [@R29], [@R34], [@R37]-[@R40], [@R43]-[@R48], [@R50]-[@R52], [@R54]-[@R57], [@R59]-[@R66], [@R68]-[@R72], [@R74]-[@R88], [@R91], [@R99]-[@R104]\]. Thirteen articles were prospective studies, in which 4 were included in this meta-analysis \[[@R12], [@R26], [@R35], [@R36], [@R42], [@R49], [@R53], [@R58], [@R67], [@R73], [@R89], [@R90], [@R92]\]. According to the North-England evidence-based guidelines \[[@R34], [@R35]\], there was one evidence level Ib in this meta-analysis \[[@R12]\], the rest cohort studies or "outcome" researches were evidence level II.\[[@R13]-[@R15], [@R26], [@R28], [@R29], [@R34]-[@R40], [@R99]\]

###### Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Year/ Country       Participating\   Study Period   Design          Level of Evidence   Number of CRC PC   Treatment strategy                                                                                                                                                                                                  
                              Institutions                                                                                                                                                                                                                                                                                               
  --------------------------- ---------------- -------------- --------------- ------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Chua TC/ 2009/ Australia\   2                1997-2008      retrospective   IIb                 15 (15/33)         CRS+HIPEC 7 pts;\                                                                                                                                                                                                   SC 8 pts\
  \[[@R34]\]                                                                                                         HIPEC: MMC (10-20 mg/m^2^) for 90 min at 42°C using the closed abdomen technique.\                                                                                                                                  SC: FOLFOX and Bevacizumab\
                                                                                                                     No EPIC.\                                                                                                                                                                                                           No HIPEC\
                                                                                                                     SC: FOLFOX and Bevacizumab                                                                                                                                                                                          No EPIC

  Chua TC/ 2011/ Australia\   3                1988-2009      retrospective   IIa                 294 (294/294)      CRS+HIPEC+SC 110 pts\                                                                                                                                                                                               Surgery and/or SC 184 pts\
  \[[@R15]\]                                                                                                         HIPEC: MMC (10-20 mg/m^2^) for 90 min at 42°C using the Coliseum technique.\                                                                                                                                        SC: 5-FU + LV; 5-FU + LV or CBP with L-OHP or CPT-11; or Regimen 2 + BEV, C225, or PAN\
                                                                                                                     No EPIC\                                                                                                                                                                                                            No EPIC\
                                                                                                                     SC: 5-FU + LV; 5-FU + LV or CBP with L-OHP or CPT-11; or Regimen 2 + BEV, C225, or PAN                                                                                                                              No HIPEC

  Chua TC/ 2013/ Australia\   1                1996-2011      prospective     IIa                 75 (75/98)         CRS+HIPEC with/without EPIC 75pts\                                                                                                                                                                                  EPIC alone 23 pts\
  \[[@R26]\]                                                                                                         HIPEC: MMC (10--12.5 mg/m^2^) or L-OHP (460 mg/m^2^) for 90 min at 42°C using the closed abdomen technique; Before starting HIEPC, oxaliplatin, 5-FU (400 mg/m^2^) and LV (20 mg/m^2^) by intravenous perfusion.\   EPIC: 5-FU (650--800 mg/m^2^/d) on Day 1-5 after surgery\
                                                                                                                     EPIC: 5-FU (650--800 mg/m^2^/d) on Day 1-5 after surgery\                                                                                                                                                           SC (not reported)\
                                                                                                                     SC (not reported)                                                                                                                                                                                                   No HIPEC
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;

###### Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Year/ Country              Participating\                                                  Study Period   Design          Level of Evidence   Number of CRC PC   Treatment strategy                                                                                                                                                             
                                     Institutions                                                                                                                                                                                                                                                                                                         
  ---------------------------------- --------------------------------------------------------------- -------------- --------------- ------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------
  Elias D/ 2001/ France \[[@R35]\]   1                                                               1993-1999      prospective     IIa                 55 (55/64)         HIPEC 27 pts\                                                                                                                                                                  EPIC37 pts\
                                                                                                                                                                           HIPEC: 1. MMC (5, 8, or 10 mg/L) for 1 h between 41 °C and 44 °C using the Coliseum technique. 2. MMC (20 mg/m^2^) + DDP (200 mg/m^2^) for 1 h between 41 °C and\              EPIC: MMC (10 g/m^2^) on Day 1 + 5-FU (500 mg/m^2^) form Day 2 to Day 6 lasted 23 h\
                                                                                                                                                                           44 °C using the Coliseum technique.\                                                                                                                                           No HIPEC\
                                                                                                                                                                           EPIC: MMC (10 g/m^2^) on Day 1 + 5-FU (500 mg/m^2^) form Day 2 to Day 6 lasted 23 h\                                                                                           No SC
                                                                                                                                                                           No SC                                                                                                                                                                          

  Elias D/ 2007/ France \[[@R36]\]   1                                                               1999-2002\     prospective     IIa                 46 (46/46)         CRS+HIPEC 23 pts\                                                                                                                                                              EPIC 23 pts\
                                                                                                     1994-2000                                                             HIPEC: L-OHP (460 mg/m^2^) for 35 min between 42-44°C using the Coliseum technique; Before starting HIEPC, 5-FU (400 mg/m^2^) and LV (20 mg/m^2^) by intravenous perfusion.\   EPIC: MMC (10 mg/m^2^) at day 0, then 5-FU (650 mg/m^2^) for the next 4days\
                                                                                                                                                                           EPIC: MMC (10 mg/m^2^) at day 0, then 5-FU (650 mg/m^2^) for the next 4days\                                                                                                   SC (not reported)\
                                                                                                                                                                           SC (not reported)                                                                                                                                                              No HIPEC

  Elias D/ 2009/ France \[[@R28]\]   6\                                                              1998-2003      retrospective   IIa                 96 (96/96)         Neoadjuvant IPC+CRS+HIPEC+SC 48 pts\                                                                                                                                           Surgery and/or SC 48 pts\
                                     (Only one centre conducted HIPEC, the rest of 5 as a control)                                                                         Neoadjuvant IPC: L-OHP or CPT-11 (not reported the detailed regimen)\                                                                                                          SC: 1. FU Plus CPT-11 or L-OHP, LV; 2. Cap Plus L-OHP; 3. CPT-11 plus C225 and CPT\
                                                                                                                                                                           HIPEC: L-OHP (460 mg/m^2^) over 30 min at 43°C using the Coliseum technique. Before starting HIEPC, 5-FU 400 mg/m^2^ and LV 20 mg/m^2^ by intravenous perfusion.\              No HIPEC\
                                                                                                                                                                           SC: 1. FU Plus CPT-11 or L-OHP, LV; 2. Cap Plus L-OHP; 3. CPT-11 plus C225 and CPT                                                                                             No EPIC
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;

###### Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Year/ Country              Participating\                                                      Study Period   Design          Level of Evidence   Number of CRC PC      Treatment strategy                                                                                                                                                                                                                                                             
                                     Institutions                                                                                                                                                                                                                                                                                                                                                                                                                
  ---------------------------------- ------------------------------------------------------------------- -------------- --------------- ------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------
  Elias D/ 2010/ France \[[@R14]\]   25\                                                                 1990-2007      retrospective   IIa                 523 (523/523)         CRS+HIPEC with/without SC 443 pts\                                                                                                                                                                                                                                             CRS+EPIC with/without SC 84 pts\
                                     (a central database)                                                                                                                         CRS+HIPEC+EPIC with/without SC 9 pts\                                                                                                                                                                                                                                          EPIC: MMC (10 g/m^2^) on Day 1+5-FU (600 mg/m^2^) form Day 2 to Day 6 lasted 23 h\
                                                                                                                                                                                  HIPEC: 1. MMC (30-50 mg/m^2^) ± DDP (50-100 mg/m^2^) during 60 to 120min at 41°C using Coliseum or closed abdomen technique; 2. L-OHP (360-460 mg/m^2^)±CPT-11 (200 mg/m^2^) +intravenous 5-FU and LV during 30 minutes at 43°C using Coliseum or closed abdomen technique.\   SC: not reported the detailed regimen\
                                                                                                                                                                                  EPIC: MMC (10 g/m^2^) on Day 1+5-FU (600 mg/m^2^) form Day 2 to Day 6 lasted 23 h\                                                                                                                                                                                             No HIPEC
                                                                                                                                                                                  SC: not reported the detailed regimen                                                                                                                                                                                                                                          

  Esquivel J/ 2014 / America\        21\                                                                 1985-2012      retrospective   IIa                 1,013 (1,013/1,013)   CRS+HIPEC 705 pts\                                                                                                                                                                                                                                                             SC alone 308 pts\
  \[[@R29]\]                         (The American Society of Peritoneal Surface Malignancies (ASPSM))                                                                            HIPEC: The chemotherapy drugs L-OHP or MMC or others but not reported the remaining details.\                                                                                                                                                                                  SC (not detailed reported)\
                                                                                                                                                                                  SC (not detailed reported)\                                                                                                                                                                                                                                                    No EPIC\
                                                                                                                                                                                  No EPIC                                                                                                                                                                                                                                                                        No HIPEC

  Franko J/ 2010/ America\           3\                                                                  2001-2007      retrospective   IIa                 105 (105/105)         CRS+HIPEC+SC 67 pts\                                                                                                                                                                                                                                                           Surgery + SC 38 pts\
  \[[@R37]\]                         (one centre conducted HIPEC, two centre as a control)                                                                                        HIPEC: MMC 30mg for the first hour, followed by an additional 10 mg for 40 more minutes using the closed abdomen technique. (Perfusion fluid temperature not reported)\                                                                                                        SC: 1. 5-FU and CPT-11; 2. L-OHP or biological agents (BEV and/or C225)\
                                                                                                                                                                                  No EPIC\                                                                                                                                                                                                                                                                       No EPIC\
                                                                                                                                                                                  SC: 1. 5-FU and CPT-11; 2. L-OHP or biological agents (BEV and/or C225)                                                                                                                                                                                                        No HIPEC
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;

###### Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Year/ Country                 Participating\         Study Period   Design          Level of Evidence   Number of CRC PC   Treatment strategy                                                                                                                                                             
                                        Institutions                                                                                                                                                                                                                                                                
  ------------------------------------- ---------------------- -------------- --------------- ------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------
  Gervais MK/ 2013/ Canada \[[@R38]\]   1                      2004-2011      retrospective   IIa                 40 (40/40)         Neoadjuvant SC with/without neoadjuvant radiotherapy+ CRS+HIPEC+SC 25 pts\                                                                                                     Neoadjuvant SC with/without neoadjuvant radiotherapy + surgery + SC 15 pts\
                                                                                                                                     Neoadjuvant SC: BEV\                                                                                                                                                           Neoadjuvant SC: BEV\
                                                                                                                                     HIPEC: L-OHP (460 mg/m^2^) for 30 min between 42-44°C using the Coliseum technique; Before starting HIEPC, 5-FU (400 mg/m^2^) and LV (20 mg/m^2^) by intravenous perfusion.\   SC: 5-FU, LV, L-OHP, and/or CPT-11, with or without BEV\
                                                                                                                                     No EPIC\                                                                                                                                                                       No EPIC\
                                                                                                                                     SC: 5-FU, LV, L-OHP, and/or CPT-11, with or without BEV                                                                                                                        No HIPEC

  Glehen O/ 2004/ France \[[@R13]\]     28\                    1987-2002      retrospective   IIa                 506 (506/506)      CRS+HIPEC with/without SC 383 pts\                                                                                                                                             CRS+EPIC with/without SC 235 pts\
                                        (a central database)                                                                         CRS+HIPEC with/without EPIC/SC 112 pts\                                                                                                                                        EPIC:\
                                                                                                                                     HIPEC: MMC/MMC+DDP, L-OHP, MMC+CPT-11, 5-FU, others during 30 to 90 min at 40-43°C using Coliseum or closed abdomen technique.\                                                5-FU (15 mg/kg/d) on Day 1-5 after surgery\
                                                                                                                                     EPIC: 5-FU (15 mg/kg/d) on Day 1-5 after surgery\                                                                                                                              SC: 1. 5-FU + LV with/without DDP/L-OHP; 2. 5-FU alone; 3. 5-FU + LV+ L-OHP+ CPT-11; 4. Others and unknown\
                                                                                                                                     SC: 1. 5-FU + LV with/without DDP/L-OHP; 2. 5-FU alone; 3. 5-FU + LV+ L-OHP+ CPT-11; 4. Others and unknown                                                                     No HIPEC

  Goéré D/ 2015/ France \[[@R99]\]      1                      2000-2010      retrospective   IIa                 139 (139/180)      Neoadjuvant SC +CRS+HIPEC+SC with/without EPIC 139 pts\                                                                                                                        Neoadjuvant SC +Surgery+SC 41 pts\
                                                                                                                                     HIPEC: L-OHP+CPT-11 (72%), CPT-11 alone (15%), other items not reported.\                                                                                                      SC: 1. 5-FU + L-OHP; 2. 5-FU + CPT-11; 3. 5-FU alone
                                                                                                                                     SC: 1. 5-FU + L-OHP; 2. 5-FU + CPT-11; 3. 5-FU alone\                                                                                                                          
                                                                                                                                     EPIC: MMC/5-FU                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;

###### Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Year/ Country                      Participating\   Study Period   Design          Level of Evidence   Number of CRC PC   Treatment strategy                                                                                                                    
                                             Institutions                                                                                                                                                                                                                 
  ------------------------------------------ ---------------- -------------- --------------- ------------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  Huang CQ/ 2014/ China \[[@R39]\]           1                2004-2013      retrospective   IIa                 62 (62/62)         CRS+HIPEC+SC with/without PIC 33 pts\                                                                                                 CRS+ SC with/without PIC 29 pts\
                                                                                                                                    HIPEC: MMC (30 mg) + DDP (120 mg) for 90 min at 43.0±0.5°C using the Coliseum technique\                                              SC: FOLFOX or FOLFIRI\
                                                                                                                                    EPIC: DXL (75 mg/m^2^, on day 1, every 3 weeks) and CBP (at Calvert formula: area under the curve, AUC 5; on day 1, every 3 weeks)\   EPIC: DXL (75 mg/m^2^, on day 1, every 3 weeks) and CBP (at Calvert formula: AUC 5; on day 1, every 3 weeks)\
                                                                                                                                    SC: FOLFOX or FOLFIRI                                                                                                                 No HIPEC

  Passot G/ 2014/ France \[[@R40]\]          1                2005-2012      retrospective   IIa                 82 (82/115)        Neoadjuvant SC+CRS+HIPEC 82 pts\                                                                                                      Neoadjuvant SC + Surgery + SC 33 pts\
                                                                                                                                    Neoadjuvant SC: 1. FOLFIRI with/without BEV or C225; 2. FOLFOX with/without BEV or C225; 3. Others regimens.\                         Neoadjuvant SC: 1. FOLFIRI with/without BEV or C225; 2. FOLFOX with/without BEV or C225; 3. Others regimens.\
                                                                                                                                    HIPEC: L-OHP (360 mg/m^2^) for 30 min using the closed abdomen technique, not reported the perfusion temperature.\                    No EPIC\
                                                                                                                                    No EPIC\                                                                                                                              SC (uncertainty)
                                                                                                                                    No SC                                                                                                                                 

  Verwaal VJ/ 2003 /Netherlands \[[@R12]\]   1                1998-2001      prospective     Ib                  87 (87/105)        CRS+HIPEC with/without SC 54 pts\                                                                                                     Surgery and/or SC 51 pts\
                                                                                                                                    HIPEC: MMC (17.5 mg/m^2^) for 90 min between 42-44°C using the Coliseum technique\                                                    SC: 1. 5-FU (400 mg/m^2^) + LV (80 mg/m^2^); 2. FU + CPT-11 (350 mg/m^2^)\
                                                                                                                                    No EPIC\                                                                                                                              No EPIC\
                                                                                                                                    SC: 1. 5-FU (400 mg/m^2^) + LV (80 mg/m^2^); 2. FU + CPT-11 (350 mg/m^2^)                                                             No HIPEC
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;

###### Major Characteristics of Sixty-one Single Arm Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                  Participating\   Study Period   Design          Level of evidence   Number of CRC PC   HIPEC
                                          Institutions                                                                           
  --------------------------------------- ---------------- -------------- --------------- ------------------- ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Alzahrani/ 2015/ Australia \[[@R41]\]   1                1996-2014      retrospective   III                 205 (205/675)      Before HIPEC, 5-FU (400 mg/m^2^) were delivered by systemic i.v., L-OHP (350 mg/m^2^) for 30 min at 43°C using coliseum technique.

  Beaujard/ 2000/ France \[[@R42]\]       1                1991-1997      prospective     IIb                 27 (27/86)         MMC (10 mg/L) for 90 min at inflow temperature 46-49 °C using the closed abdomen technique.

  Bijelic/ 2008/ Australia \[[@R43]\]     1                1981-2004      retrospective   III                 70 (70/472)        MMC (10 mg/m^2^ for females and 12.5 mg/m^2^ for males) for 90 min at about 42 °C using the coliseum technique.

  Braam/ 2014/ Australia \[[@R44]\]       2                2005-2013      retrospective   III                 132 (132/132)      MMC (17.5 mg/m^2^ an additional 8.8 mg/m^2^ at an interval of 30 and 60 min) for 90 min at 42 °C using the coliseum technique.

  Cao/ 2009/ Australia \[[@R45]\]         1                1995-2008\`    retrospective   III                 52 (52/467)        MMC (10-12.5 mg/m^2^) for 90 min at 42 °C using coliseum technique.

  Cavaliere/ 2006/ Italy \[[@R46]\]       6                1996-2005      retrospective   III                 120 (120/120)      MMC (3.3 mg/m^2^/L) + DDP (25 mg/m^2^/L) for 60-90 min at 41.5-43 °C using the coliseum or closed abdomen technique.\
                                                                                                                                 After intravenous administration of 5-FU (400 mg/m^2^) and LV (20 mg/m^2^), L-OHP (460 mg/m^2^) for 30 min at 43 °C using the coliseum or closed abdomen technique.

  Ceelen/ 2014/ Belgium \[[@R47]\]        1                2002-2012      retrospective   III                 152 (152/166)      Before HIPEC, LV (20 mg/m^2^) and 5-FU (400 mg/m^2^) were delivered by systemic i.v. L-OHP (460 mg/m^2^) or MMC (35 mg/m^2^) for 30-90 min at 41 °C using coliseum technique.

  Desantis/ 2014/ Franc^e^ \[[@R48]\]     1                1999-2011      retrospective   III                 74 (74/356)        MMC (10 mg/m^2^ for females and 12.5 mg/m^2^ for males) for 90 min at 43°C using coliseum or closed abdomen technique.

  Elias/ 2004/ France \[[@R49]\]          1                1998-2001      prospective     IIb                 24 (24/24)         One hour before HIPEC, LV (20 mg/m^2^) and 5-FU (400 mg/m2) were delivered by systemic i.v.\
                                                                                                                                 HIPEC: L-OHP (460 mg/m^2^) for 30 min at 43 °C using the coliseum technique.

  Elias/ 2014/ France \[[@R50]\]          1                1995-2010      retrospective   III                 119 (119/443)      MMC (5, 8, or 10 mg/L) for 1 h between 41 °C and 44 °C using the coliseum technique.\
                                                                                                                                 MMC (20 mg/m^2^) + DDP (200 mg/m^2^) for 1 h between 41 °C and 44 °C using the coliseum technique.\
                                                                                                                                 L-OHP 460 mg/m^2^ over 30 min at 43°C using the coliseum technique.\
                                                                                                                                 MMC (12.9+/-3.8 mg/m^2^) for 90 min between 41 °C and 42 °C using closed abdomen technique.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; NR: not reported

###### Major Characteristics of Sixty-one Single Arm Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                     Participating\   Study Period   Design          Level of evidence   Number of CRC PC   HIPEC
                                             Institutions                                                                           
  ------------------------------------------ ---------------- -------------- --------------- ------------------- ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Evers/ 2011/ Netherlands \[[@R51]\]        1                2001-2009      retrospective   III                 108 (108/194)      MMC (35 mg/m^2^) for 90 min at 40-41 °C, perfusion mode not reported.

  Faron M/ 2016/ France \[[@R100]\]          1                2003-2012      retrospective   III                 173 (173/173)      Before HIPEC, LV (20 mg/m^2^) and 5-FU (400 mg/m2) were delivered by systemic i.v.\
                                                                                                                                    HIPEC: L-OHP (300 mg/m^2^) and CPT-11 (200 mg/m^2^) for 30 min between 43 °C using closed abdomen technique.

  Franko/ 2008/ America \[[@R52]\]           1                2001-2007      retrospective   III                 65 (65/65)         MMC (40 mg/m^2^) for 90 min using closed abdomen technique. (have not reported the liquid perfusion temperature)

  Frøysnes/ 2016/ Norway\[[@R103]\]          1                2004-2013      retrospective   III                 119 (119/144)      MMC (35 mg/m^2^) for 90 min between 39.5 °C and 41.2 °C using closed abdomen technique until 2008, and thereafter a closed technique with open abdomen

  Glehen/ 2003/ France \[[@R53]\]            1                1998-2001      prospective     IIb                 26 (26/56)         MMC (0.7 mg/kg) for 90 min at 46-48 °C using closed abdomen technique.

  Glehen/ 2004/ France \[[@R16]\]            1                1989-2002      retrospective   III                 53 (53/53)         MMC (total dose 40-60 mg) for 90 min at 46-48 °C using closed abdomen technique.

  Glehen/ 2010/ France \[[@R54]\]            25               1989-2007      retrospective   III                 523 (523/1290)     MMC (30-50 mg/m^2^) with or without DDP (50-100 mg/m^2^) for 60-120 min at 41-42.5 °C using the coliseum or closed abdomen technique.\
                                                                                                                                    L-OHP (360-460 mg/m^2^) with or without CPT-11 (100-200 mg/m^2^) with or without intravenous 5-FU and LV delivered over 30 min at 43°C using the coliseum or closed abdomen technique.

  Gomes da Silva/ 2005/ America \[[@R55]\]   1                1981-2004      retrospective   III                 11 (11/11)         MMC (10 mg/m^2^ in females and 12.5 mg/m^2^ in males) for 90 min at 41-42 °C using closed abdomen technique.

  Gusani/ 2008/ America \[[@R56]\]           1                2002-2005      retrospective   III                 28 (25/122)        MMC (30 mg) for 60 min at 40-42 °C using closed abdomen technique, after 60 min, additional MMC (10 mg) was added for 40 more min.

  Hamilton/ 2011/ Canada \[[@R57]\]          1                2000-2008      retrospective   III                 31 (31/101)        MMC (12-15 mg) for 90 min at 40-42 °C using coliseum technique.

  Hompes/ 2012/ Belgium \[[@R58]\]           6                2004-2008      prospective     IIb                 39 (39/48)         L-OHP (460 mg/m^2^) for 30 min at 41-42 °C using coliseum technique. Before HIPEC, systemic\
                                                                                                                                    LV (20 mg/m^2^) and 5-FU (400 mg/m^2^) were administered.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; NR: not reported

###### Major Characteristics of Sixty-one Single Arm Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                               Participating\   Study Period   Design          Level of evidence   Number of CRC PC   HIPEC
                                                       Institutions                                                                           
  ---------------------------------------------------- ---------------- -------------- --------------- ------------------- ------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hompes/ 2014/ Belgium \[[@R59]\]                     2                2004-2006\     retrospective   IIb                 95 (95/95)         MMC (35 mg/m^2^) for 90 min at 41-42 °C using coliseum or closed abdomen technique.\
                                                                        2006-2010                                                             Before HIPEC, LV (20 mg/m^2^) and 5-FU (400 mg/m^2^) were delivered by systemic i.v. L-OHP (460 mg/m^2^) for 30 min at 41-42 °C using coliseum or closed abdomen technique.

  Iversen/ 2013/ Denmark \[[@R60]\]                    1                2006-2012      retrospective   III                 34 (34/80)         MMC (35 mg/m^2^) for 90 min at 41.0-42.5 °C using coliseum technique.

  Kecmanovic/ 2005/ Serbia and Montenegro \[[@R61]\]   1                1996-2003      retrospective   III                 18 (18/18)         MMC (12.5 mg/m^2^, max. 25 mg for males; 10.0 mg/m^2^, max. 20 mg for females) for 120 min at 42 °C using closed abdomen technique

  Kianmanesh/ 2007/ France \[[@R62]\]                  1                1992-2005      retrospective   III                 43 (43/43)         MMC (120 mg) + DDP (200 mg/m^2^) for 90-120 min at 47-50 °C using coliseum or closed abdomen technique.

  Klaver/ 2011/ Netherlands \[[@R63]\]                 1                1997-2008      retrospective   III                 21 (21/21)         MMC (35 mg/m^2^) for 90 min at 41°C using coliseum technique.

  Klaver/ 2012/ Netherlands \[[@R64]\]                 2                1996-2010      retrospective   III                 17 (17/24)         MMC or L-OHP for 90 min at 42°C using coliseum technique.

  Kuijpers/ 2013/ Netherlands \[[@R65]\]               6                1995-2012      retrospective   III                 660 (660/960)      MMC (35 mg/m^2^) (in three fractions (one half, one fourth, and one fourth of the total dose)) for 90 min at 41-42 °C using coliseum technique.

  Kuijpers/ 2014/ Netherlands \[[@R66]\]               1                2004-2012      retrospective   III                 73 (73/73)         MMC (35 mg/m^2^) for 90 min at 41-42 °C using coliseum technique.

  Lanuke/ 2009/ Canada\                                1                2000-2008      prospective     IIb                 31 (31/101)        MMC (12-15 mg) for 60 min at 40-42 °C using coliseum technique.
  \[[@R67]\]                                                                                                                                  

  Levine/ 2014/ America\                               1                1991-2013      retrospective   III                 232 (232/1000)     MMC (30 mg) for 60-90 min at 38.5-43 °C using coliseum technique; L-OHP (200 mg/m^2^) for selected patients.
  \[[@R68]\]                                                                                                                                  

  Maillet M/ 2016/ France \[[@R101]\]                  4                2004-2012      retrospective   III                 231 (231/231)      NR

  McConnell/ 2013/ Canada \[[@R69]\]                   1                2000-2011      retrospective   III                 245 (245/245)      MMC (12-15 mg) for 60 min at 40-42 °C using coliseum or closed abdomen technique.\
                                                                                                                                              L-OHP (400 mg/m^2^) for 60 min at 40-42 °C using coliseum or closed abdomen technique with a simultaneous dose of intravenous 5-FU (800 mg)..

  Nikolic/ 2014/ Serbia\                               1                2005-2012      retrospective   III                 61 (61/61)         L-OHP (410 mg/m^2^) for 30-60 min at 41 °C using closed abdomen technique.
  \[[@R70]\]                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; NR: not reported

###### Major Characteristics of Sixty-one Single Arm Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                        Participating\   Study Period   Design          Level of evidence   Number of CRC PC   HIPEC
                                                Institutions                                                                           
  --------------------------------------------- ---------------- -------------- --------------- ------------------- ------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Passot/ 2012/ France\                         1                1991-2010      retrospective   III                 120 (120/120)      MMC (10 mg/ml, total dose 40-60mg) for 90 min at 46-48 °C using closed abdomen technique.\
  \[[@R21]\]                                                                                                                           MMC (0.7 mg/kg) + CPT-11 (100 mg/m^2^) for 90 min at 44-46 °C using closed abdomen technique.\
                                                                                                                                       MMC (30-50 mg/m^2^) with or without DDP (50-100 mg/m^2^) for 60-120 min at 41-42.5 °C using coliseum technique or closed abdomen technique.\
                                                                                                                                       L-OHP (360-460 mg/m^2^) with or without CPT-11 (100-200 mg/m^2^) with or without intravenous 5-FU and LV for 30 min at 43°C using coliseum technique or closed abdomen technique.

  Passot/ 2016/ France\                         1                1989-2015      retrospective   III                 342 (342/1,125)    Idem (Passot/ 2012/ France \[[@R21]\])
  \[[@R104]\]                                                                                                                          

  Pilati/ 2003/ Italy\                          1                1995-2001      retrospective   III                 46 (46/46)         MMC (3.3 mg/m^2^/L) with or without DDP (25 mg/m^2^/L) for 90 min at 41.2-42.1 °C using coliseum technique or closed abdomen technique.
  \[[@R71]\]                                                                                                                           

  Prada-Villaverde/ 2014/ Spai^n^ \[[@R72]\]    15               2000-2011      retrospective   III                 539 (539/539)      MMC or L-OHP for 30-120 min at 40-43°C using coliseum or closed abdomen technique.

  Quenet/ 2011/ France \[[@R73]\]               2                1998-2007\     prospective     IIb                 146 (146/146)      L-OHP (460 mg/m^2^) with intravenous 5-FU (400 mg/m^2^) and LV (20 mg/m^2^) for 30 min at 42-45 °C using coliseum technique.\
                                                                 2002-2007                                                             L-OHP (300 mg/m^2^) with CPT-11 (200 mg/m^2^) with intravenous 5-FU (400 mg/m^2^) and LV (20 mg/m^2^) for 30 min at 42-45 °C using coliseum technique.

  Rivard/ 2014/ Canada \[[@R74]\]               1                2003-2011      retrospective   III                 68 (68/68)         NR

  Rodt/ 2013/ Denmark \[[@R75]\]                1                2006-2011      retrospective   III                 19 (19/35)         NR

  Shen/ 2004/ America\                          1                1991-2002      retrospective   III                 77 (77/77)         MMC (total dose 30 mg) for 60-120 min at 38.5-43 °C using closed abdomen technique.
  \[[@R20]\]                                                                                                                           

  Shen/ 2008/ America\                          1                1992-2005      retrospective   III                 55 (55/150)        MMC (total dose 30 mg) for 60-120 min at 38.5-43 °C using closed abdomen technique.
  \[[@R76]\]                                                                                                                           

  Simkens GA/ 2015/ Netherlands \[[@R102]\]     1                2007-2013      retrospective   III                 133 (133/133)      MMC (35 mg/m^2^) for 90 min at 41.1 °C using open-coliseum technique.

  Swellengrebel/ 2009/ Netherlands \[[@R77]\]   1                1999-2005      retrospective   III                 92 (92/92)         MMC (35 mg/m^2^) for 90 min at 41-42 °C using coliseum technique.
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; NR: not reported

###### Major Characteristics of Sixty-one Single Arm Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                          Participating\   Study Period   Design          Level of evidence   Number of CRC PC   HIPEC
                                                  Institutions                                                                           
  ----------------------------------------------- ---------------- -------------- --------------- ------------------- ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tabrizian/ 2014/ America \[[@R78]\]             1                2007-2012      retrospective   III                 51 (51/170)        MMC (total dose 40 mg) for 90 min at 41-43 °C using closed abdomen technique.

  Teo/ 2013/ Singapore\                           1                2001-2012      retrospective   III                 28 (28/100)        MMC for 60 min at 42 °C using closed abdomen technique.
  \[[@R79]\]                                                                                                                             

  Teo/ 2014/ Singapore\                           1                2001-2012      retrospective   III                 35 (35/35)         MMC for 60 min at 42 °C using closed abdomen technique.
  \[[@R80]\]                                                                                                                             

  Ung/ 2013/ Australia\                           1                2000-2012      retrospective   III                 125 (125/211)      MMC (12.5 mg/m^2^) for 90 min at 42 °C using coliseum technique.
  \[[@R81]\]                                                                                                                             

  Vaira/ 2010/ Italy \[[@R82]\]                   1                2002-2008      retrospective   III                 40 (40/72)         MMC (16 mg/m^2^) + DDP (100 mg/m^2^) for 60 min at 41.5 °C using semi-closed abdomen technique.\
                                                                                                                                         Before HIPEC, LV (20 mg/m^2^) and 5-FU (400 mg/m^2^) were delivered by systemic i.v. L-OHP (460 mg/m^2^) for 30 min at 42 °C using semi-closed abdomen technique.

  van Leeuwen / 2008/ Sweden \[[@R83]\]           1                2003-2006      retrospective   III                 38 (38/103)        Before HIPEC, LV (30 mg/m^2^) and 5-FU (500 mg/m^2^) were delivered by systemic i.v.\
                                                                                                                                         HIPEC: L-OHP (460 mg/m^2^) for 30 min at 42-44 °C using the coliseum technique.

  van Oudheusden/ 2014/ Netherlands \[[@R84]\]    2                2005-2013      retrospective   III                 113 (113/149)      MMC (35 mg/m^2^) for 90 min at 41-42 °C using coliseum technique.

  van Oudheusden / 2015/ Netherlands \[[@R85]\]   2                2005-2013      retrospective   III                 252 (252/351)      MMC (35 mg/m^2^) for 90 min at 41.1 °C using open-coliseum technique.

  Varban/ 2009/ America\                          1                1991-2007      retrospective   III                 128 (128/142)      MMC (total dose 30 mg) for 60 or 90 min at 42.5 °C using closed abdomen technique.\
  \[[@R86]\]                                                                                                                             MMC (total dose 40 mg) for 120 min at 42.5 °C using closed abdomen technique.

  Verwaal/ 2005/ Netherlands \[[@R19]\]           1                1995-2003      retrospective   III                 117 (117/117)      MMC (35 mg/m^2^) for 90 min at 40-41 °C using coliseum technique.

  Votanopoulos/ 2013/ America \[[@R87]\]          1                1993-2011      retrospective   III                 217 (217/217)      MMC for 90-120 min at 40.5-43 °C using closed abdomen technique.

  Winer/ 2014/ America\                           1                2001-2011      retrospective   III                 30 (30/67)         MMC (total dose 40 mg) for 100 min at 42 °C using closed abdomen technique.
  \[[@R88]\]                                                                                                                             

  Witkamp/ 2001/ Netherlands \[[@R89]\]           1                1995-1997      prospective     IIb                 29 (29/29)         MMC (15-40 mg/m^2^ initially; 35 mg/m^2^ majority) for 90 min at 40-41 °C using closed abdomen technique.

  Yan/ 2006/ Australia\                           1                1997-2006      prospective     IIb                 30 (30/30)         MMC (10-12.5 mg/m^2^) for 90 min at 42 °C using coliseum technique.
  \[[@R90]\]                                                                                                                             

  Yan/ 2008/ Australia\                           1                1997-2007      retrospective   III                 50 (50/50)         MMC (10-12.5 mg/m^2^) for 90 min at 42 °C using coliseum technique.
  \[[@R91]\]                                                                                                                             

  Zanon/ 2006/ Italy \[[@R92]\]                   1                1998-2004      prospective     III                 25 (25/25)         MMC (15 mg/m^2^) for 60 min at 42 °C using closed abdomen technique.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; NR: not reported

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\                                                                                                Major Institutions                                                                                    No. patients   Mode                 HIPEC-MMC alone   HIPEC-MMC+DDP   HIPEC-L-OHP alone   HIPEC-other       Temperature\
  /No. Institutions                                                                                                                                                                                                                                                                                                         (°C)
  ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- -------------- -------------------- ----------------- --------------- ------------------- ----------------- --------------
  USA, 17                                                                                                 Wake Forest University of Baptist Medical Center \[[@R13], [@R20], [@R68], [@R76], [@R86], [@R87]\]                                                                                                               

  Subtotal/Median/Range                                                                                   \>709                                                                                                 C              30 mg                                                                      40.75 (38.5-43)   90 (60-90)

  University of Pittsburgh Medical Center (University of Pittsburgh) \[[@R37], [@R52], [@R56], [@R88]\]                                                                                                                                                                                                                     

  Subtotal/Median/Range                                                                                   190                                                                                                   C              40 mg                                                                      42 (40-42)        100 (90-100)

  Washington Hospital Center \[[@R13], [@R43], [@R55]\]                                                                                                                                                                                                                                                                     

  Subtotal/Median/Range                                                                                   \>81                                                                                                  C              10 or 12.5 mg/m^2^                                                         42 (40-43)        90 (30-90)

  Cancer Treatment Centers of America \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                    

  Subtotal/Median/Range                                                                                   ?                                                                                                     O/C            Y                                      Y                                   40-43             30-120

  Loma Linda University Medical Center \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                   

  Subtotal/Median/Range                                                                                   ?                                                                                                     O/C            Y                                      Y                                   40-43             30-120

  Medical College of Wisconsin \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                           

  Subtotal/Median/Range                                                                                   ?                                                                                                     O/C            Y                                      Y                                   40-43             30-120

  Mercy Medical Center \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                                   

  Subtotal/Median/Range                                                                                   ?                                                                                                     O/C            Y                                      Y                                   40-43             30-120

  Moores Cancer Center, University of California \[[@R29], [@R72]\]                                                                                                                                                                                                                                                         

  Subtotal/Median/Range                                                                                   ?                                                                                                     O/C            Y                                      Y                                   40-43             30-120

  Rutgers University \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                                     

  Subtotal/Median/Range                                                                                   ?                                                                                                     O/C            Y                                      Y                                   40-43             30-120

  St Agnes Hospital \[[@R15], [@R34]\]                                                                                                                                                                                                                                                                                      

  Subtotal/Median/Range                                                                                   \>30                                                                                                  O/C            10-20 mg/m^2^                                                              42                90
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\                                                                 Major Institutions                                                                                                            No. patients   Mode            HIPEC-MMC alone                  HIPEC-MMC+DDP     HIPEC-L-OHP alone                                    HIPEC-other        Temperature\     Duration\
  /No. Institutions                                                                                                                                                                                                                                                                                                                                                (°C)             (min)
  ------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------- -------------- --------------- -------------------------------- ----------------- ---------------------------------------------------- ------------------ ---------------- ----------------
  USA, 17                                                                  St. John Hospital \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                     

  Subtotal/Median/Range                                                    ?                                                                                                                             O/C            Y                                                Y                                                                      40-43              30-120           

  Tufts Medical Center \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                                                                                           

  Subtotal/Median/Range                                                    ?                                                                                                                             O/C            Y                                                Y                                                                      40-43              30-120           

  University of Illinois \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                                                                                         

  Subtotal/Median/Range                                                    ?                                                                                                                             O/C            Y                                                Y                                                                      40-43              30-120           

  University of Miami \[[@R29], [@R72]\]                                                                                                                                                                                                                                                                                                                                            

  Subtotal/Median/Range                                                    ?                                                                                                                             O/C            Y                                                Y                                                                      40-43              30-120           

  American Society of Peritoneal Surface Malignancies (ASPSM) \[[@R29]\]   ?                                                                                                                             NR             Y                                                Y                 others                                               NR                 NR               

  Mount Sinai Medical Center \[[@R78]\]                                    51                                                                                                                            C              40 mg                                                                                                                   41-43              90               

  Sharp Health Care \[[@R13]\]                                             ?                                                                                                                             O/C            Y               Y                                Y                 MMC+CPT-11, 5-FU                                     40-43              30-90            

  Subtotal                                                                                                                                                                                               \>1061         C               30/40 mg\                                          Y, 200 mg/m2                                         MMC+CPT-11, 5-FU   42 (40-43)       90 (60-90) /30
                                                                                                                                                                                                                                        10-20 mg/m2\                                                                                                                                
                                                                                                                                                                                                                                        10 or 12.5 mg/m2                                                                                                                            

  France, 14                                                               Centre Hospitalo-Universitaire Lyon Sud \[[@R14], [@R16], [@R21], [@R29], [@R13], [@R40], [@R42], [@R53], [@R72], [@R101]\]                                                                                                                                                                              

  Subtotal/Median/Range                                                    \>500                                                                                                                         C              10 mg/L\        30-50 mg/m^2^ + 50-100 mg/m^2^   360 mg/m^2^\      MMC+CPT-11, 5-FU\                                    44 (46-48) /43     90 (60-90) /30   
                                                                                                                                                                                                                        0.7 mg/kg\                                       360-460 mg/m^2^   MMC (0.7 mg/kg) + CPT-11 (100 mg/m^2^)\                                                  
                                                                                                                                                                                                                        40-60 mg\                                                          L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)                                       
                                                                                                                                                                                                                        30-50 mg/m^2^                                                                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------- --------------------- -------------------------------- ----------------- ----------------------------------------------------- ------------------ ----------------------- -----------
  Country\                                                             Major Institutions                                                                                                    No. patients   Mode                  HIPEC-MMC alone                  HIPEC-MMC+DDP     HIPEC-L-OHP alone                                     HIPEC-other        Temperature\            Duration\
  /No. Institutions                                                                                                                                                                                                                                                                                                                                           (°C)                    (min)

  France, 14                                                           Gustave Roussy Institute \[[@R13], [@R14], [@R28], [@R35], [@R36], [@R49], [@R50], [@R54], [@R73], [@R99]-[@R101]\]                                                                                                                                                                                            

  Subtotal/Median/Range                                                \>700                                                                                                                 O              5, 8, or 10 mg/L\     20 mg/m^2^ + 200 mg/m^2^\        460 mg/m^2^\      MMC+CPT-11, 5-FU\                                     43 (41-44) /43     60 (60-90) /30          
                                                                                                                                                                                                            20 mg/m^2^\           30-50 mg/m^2^ + 50-100 mg/m^2^   360-460 mg/m^2^   L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)\                                              
                                                                                                                                                                                                            12.9+/-3.8 mg/m^2^\                                                      L-OHP (300 mg/m^2^) + CPT-11 (200 mg/m^2^)                                                       
                                                                                                                                                                                                            30-50 mg/m^2^                                                                                                                                                             

  Val d'Aurelle Center \[[@R13], [@R14], [@R54], [@R73]\]                                                                                                                                                                                                                                                                                                                             

  Subtotal/Median/Range                                                \>66                                                                                                                  O              30-50 mg/m^2^         30-50 mg/m^2^ + 50-100 mg/m^2^   460 mg/m^2^\      L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)\   43.5 (40-43) /43   60 (60-90) /30          
                                                                                                                                                                                                                                                                   360-460 mg/m^2^   L-OHP (300 mg/m^2^) + CPT-11 (200 mg/m^2^)                                                       

  Centre Hospitalo-Universitaire l'Archet \[[@R13], [@R14], [@R54]\]                                                                                                                                                                                                                                                                                                                  

  Subtotal/Median/Range                                                \>25                                                                                                                  O/C            30-50 mg/m^2^         30-50 mg/m^2^ + 50-100 mg/m^2^   360-460 mg/m^2^   L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)    41.5 (41-43) /43   60 (60-90) /30 or 60    

  Paul Papin Institute \[[@R13], [@R14], [@R54]\]                                                                                                                                                                                                                                                                                                                                     

  Subtotal/Median/Range                                                \>25                                                                                                                  O/C            30-50 mg/m^2^         30-50 mg/m^2^ + 50-100 mg/m^2^   360-460 mg/m^2^   L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)    41.5 (41-43) /43   60 (60-90) /30 or 60    

  French Association of Surgery \[[@R14], [@R54]\]                                                                                                                                                                                                                                                                                                                                    

  Subtotal/Median/Range                                                ?                                                                                                                     O/C            30-50 mg/m^2^         30-50 mg/m^2^ + 50-100 mg/m^2^   360-460 mg/m^2^   L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)    41 (41-43) /43     90 (60-120) /30 or 60   
  -------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------- --------------------- -------------------------------- ----------------- ----------------------------------------------------- ------------------ ----------------------- -----------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\                                                                Major Institutions                                              No. patients   Mode                 HIPEC-MMC alone                   HIPEC-MMC+DDP                HIPEC-L-OHP alone                                    HIPEC-other                   Temperature\       Duration\
  /No. Institutions                                                                                                                                                                                                                                                                                                             (°C)               (min)
  ----------------------------------------------------------------------- --------------------------------------------------------------- -------------- -------------------- --------------------------------- ---------------------------- ---------------------------------------------------- ----------------------------- ------------------ ----------------------
  France, 14                                                              Hospital Lariboisiere \[[@R29], [@R72]\]                                                                                                                                                                                                                                 

  Subtotal/Median/Range                                                   ?                                                               O/C            Y                                                      Y                                                                                 40-43                         30-120             

  Louis-Mourier University Hospital \[[@R62], [@R62], [@R101]\]                                                                                                                                                                                                                                                                                    

  Subtotal/Median/Range                                                   \>250                                                           O/C            30-50 mg/m^2^        30-50 mg/m^2^ + 50-100 mg/m^2^\   360-460 mg/m^2^              L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)   42 (41-42.5) /48.5 (47-50)\   90 (90-120) /60    
                                                                                                                                                                              201 mg + 200 mg/m^2^                                                                                                /30-43                                           

  Centre Hospitalier de Bellevue \[[@R13]\]                               25                                                              O/C            Y                    Y                                 Y                            MMC+CPT-11, 5-FU                                     40-43                         30-90              

  Centre Hospitalo-Universitaire Dijon \[[@R13]\]                         25                                                              O/C            Y                    Y                                 Y                            MMC+CPT-11, 5-FU                                     40-43                         30-90              

  Centre Jean Perrin \[[@R13]\]                                           25                                                              O/C            Y                    Y                                 Y                            MMC+CPT-11, 5-FU                                     40-43                         30-90              

  CHU of Nice \[[@R48]\]                                                  74                                                              O/C            10 or 12.5 mg/m^2^                                                                                                                       43                            90                 

  Lyon Civil Hospices, South Lyon University Hospital Center \[[@R54]\]   ?                                                               O/C            30-50 mg/m^2^        30-50 mg/m^2^ + 50-100 mg/m^2^    360-460 mg/m^2^              L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)   41-42.5, 30-43                90/60              

  Université Claude Bernard Lyon \[[@R13]\]                               25                                                              O/C            Y                    Y                                 Y                            MMC+CPT-11, 5-FU                                     40-43                         30-90              

  Subtotal                                                                                                                                \>1038         O                    30-50 mg/m2                       30-50 mg/m2 + 50-100 mg/m2   360-460 mg/m2                                        MMC+CPT-11, 5-FU\             41.5 (40-43) /43   60 (60-90) /30 or 60
                                                                                                                                                                                                                                                                                                  L-OHP + CPT-11 MMC + CPT-11                      

  Italy, 8                                                                National Cancer Institute of Milan \[[@R29], [@R46], [@R72]\]                                                                                                                                                                                                            

  Subtotal/Median/Range                                                   ?                                                               O/C            Y                    3.3 mg/m^2^/L + 25 mg/m^2^/L      460 mg/m^2^                                                                       42 (41.5-43) /43              60 (60-90) /30     

  San Giuseppe Hospital \[[@R13], [@R46], [@R82]\]                                                                                                                                                                                                                                                                                                 

  Subtotal/Median/Range                                                   \>65                                                            O/C            Y                    3.3 mg/m^2^/L + 25 mg/m^2^/L\     460 mg/m^2^                  MMC+CPT-11, 5-FU                                     42 (41.5-43) /43              60 (60-90) /30     
                                                                                                                                                                              16 mg/m^2^ + 100 mg/m^2^                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\                                                Major Institutions                                          No. patients   Mode            HIPEC-MMC alone                  HIPEC-MMC+DDP              HIPEC-L-OHP alone                                    HIPEC-other          Temperature\            Duration\
  /No. Institutions                                                                                                                                                                                                                                                                        (°C)                    (min)
  ------------------------------------------------------- ----------------------------------------------------------- -------------- --------------- -------------------------------- -------------------------- ---------------------------------------------------- -------------------- ----------------------- ----------------
  Italy, 8                                                Regina Elena National Cancer Institute \[[@R13], [@R46]\]                                                                                                                                                                                                

  Subtotal/Median/Range                                   \>25                                                        O/C            Y               3.3 mg/m^2^/L + 25 mg/m^2^/L     460 mg/m^2^                MMC+CPT-11, 5-FU                                     42 (41.5-43) /43     60 (60-90) /30          

  University of Padua \[[@R46], [@R71]\]                                                                                                                                                                                                                                                                           

  Subtotal/Median/Range                                   \>46                                                        O/C            3.3 mg/m^2^/L   3.3 mg/m^2^/L + 25 mg/m^2^/L     460 mg/m^2^                                                                     42 (41.5-43) /43     90 (60-90) /33          

  Istituto Nazional Tumori \[[@R13]\]                     25                                                          O/C            Y               Y                                Y                          MMC+CPT-11, 5-FU                                     40-43                30-90                   

  Ospedale di Bentivoglio \[[@R46]\]                      ?                                                           O/C                            3.3 mg/m^2^/L + 25 mg/m^2^/L     460 mg/m^2^                                                                     41.5-43/43           60-90/30                

  San Camillo-Forlanini Hospital \[[@R46]\]               ?                                                           O/C                            3.3 mg/m^2^/L + 25 mg/m^2^/L     460 mg/m^2^                                                                     41.5-43/43           60-90/30                

  San Giovanni Battista Antica Sede Hospital \[[@R92]\]   25                                                          C              15 mg/m^2^                                                                                                                       42                   60                      

  Subtotal                                                                                                            \>186          C               Y                                3.3 mg/m2/L + 25 mg/m2/L   460 mg/m2                                            MMC+CPT-11, 5-FU     42 (41.5-43) /43        60 (60-90) /30

  Belgium, 6                                              Jolimont Hospital \[[@R14],[@R54], [@R58]\]                                                                                                                                                                                                              

  Subtotal/Median/Range                                   ?                                                           O              30-50 mg/m^2^   30-50 mg/m^2^ + 50-100 mg/m^2^   360-460 mg/m^2^\           L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)   41.5 (41-42.5) /43   90 (60-120) /30 or 60   
                                                                                                                                                                                      460 mg/m^2^                                                                                                                  

  Ghent University Hospital \[[@R47], [@R58]\]                                                                                                                                                                                                                                                                     

  Subtotal/Median/Range                                   \>152                                                       O              35 mg/m^2^                                       460 mg/m^2^                                                                     41 (41-42)           60 (60-90) /30          

  University Hospitals Gasthuisberg \[[@R58], [@R59]\]                                                                                                                                                                                                                                                             

  Subtotal/Median/Range                                   \>39                                                        O                                                               460 mg/m^2^                                                                     41-42                30                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\                                                                          Major Institutions                                                                               No. patients   Mode         HIPEC-MMC alone   HIPEC-MMC+DDP                HIPEC-L-OHP alone   HIPEC-other      Temperature\        Duration\
  /No. Institutions                                                                                                                                                                                                                                                                                  (°C)                (min)
  --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ -------------- ------------ ----------------- ---------------------------- ------------------- ---------------- ------------------- ----------------------
  Belgium, 6                                                                        I-Biostat, Katholieke Universiteit Leuven and Universiteit Hasselt \[[@R58]\]                    ?              O                                                           460 mg/m^2^                          41-42               30

  UCL Mont-Godinne \[[@R58]\]                                                       ?                                                                                                O                                             460 mg/m^2^                                      41-42            30                  

  Ziekenhuis Oost-Limburg \[[@R58]\]                                                ?                                                                                                O                                             460 mg/m^2^                                      41-42            30                  

  Subtotal                                                                                                                                                                           \>191          O            30-50 mg/m2       30-50 mg/m2 + 50-100 mg/m2   460 mg/m2           L-OHP + CPT-11   41 (41-42) /41-42   90 (60-90) /30 or 60

  Netherlands, 6                                                                    Netherlands Cancer Institute \[[@R12], [@R19],[@R51], [@R59], [@R65], [@R66], [@R77], [@R89]\]                                                                                                                                       

  Subtotal/Median/Range                                                             863                                                                                              O              35 mg/m^2^                                                                      41.5 (41-42)     90                  

  Catharina Hospital Eindhoven \[[@R44], [@R63]-[@R65], [@R84], [@R85], [@R102]\]                                                                                                                                                                                                                                        

  Subtotal/Median/Range                                                             \>300                                                                                            O              35 mg/m^2^                                                                      41.5 (41-42)     90                  

  Sint Antonius Hospital Nieuwegein \[[@R44], [@R65], [@R84], [@R85]\]                                                                                                                                                                                                                                                   

  Subtotal/Median/Range                                                             \>121                                                                                            O              35 mg/m^2^                                                                      41.5 (41-42)     90                  

  Radboud University Nijmegen Medical Center \[[@R64]\]                             12                                                                                               O              35 mg/m^2^                                                                      41-42            90                  

  University Medical Center Groningen \[[@R64]\]                                    48                                                                                               O              35 mg/m^2^                                                                      41-42            90                  

  VU Medical Centre Amsterdam\                                                      17                                                                                               O              35 mg/m^2^                                                                      41-42            90                  
  \[[@R64]\]                                                                                                                                                                                                                                                                                                             

  Subtotal                                                                                                                                                                           \>1432         O            35 mg/m2                                                                            41.5 (41-42)        90

  Spain\                                                                            Hospital San Jaime \[[@R29], [@R71]\]                                                                                                                                                                                                
  6                                                                                                                                                                                                                                                                                                                      

  Subtotal/Median/Range                                                             ?                                                                                                O/C            Y                              Y                                                40-43            30-120              

  Hospital Torrecardenas \[[@R29], [@R71]\]                                                                                                                                                                                                                                                                              

  Subtotal/Median/Range                                                             ?                                                                                                O/C            Y                              Y                                                40-43            30-120              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\                                                                           Major Institutions                                                                                               No. patients   Mode            HIPEC-MMC alone                  HIPEC-MMC+DDP                    HIPEC-L-OHP alone                                    HIPEC-other                  Temperature\                 Duration\
  /No. Institutions                                                                                                                                                                                                                                                                                                                                                                      (°C)                         (min)
  ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- -------------- --------------- -------------------------------- -------------------------------- ---------------------------------------------------- ---------------------------- ---------------------------- -----------------------------
  Spain, 6                                                                           M. D. Anderson Cancer Center \[[@R29], [@R71]\]                                                                                                                                                                                                                                                                                  

  Subtotal/Median/Range                                                              ?                                                                                                                O/C            Y                                                Y                                                                                     40-43                        30-120                       

  San Jose Hospital \[[@R29], [@R71]\]                                                                                                                                                                                                                                                                                                                                                                                

  Subtotal/Median/Range                                                              ?                                                                                                                O/C            Y                                                Y                                                                                     40-43                        30-120                       

  Hospital Infanta Cristina\                                                         ?                                                                                                                O/C            Y                                                Y                                others                                               40-43                        30-120                       
  \[[@R71]\]                                                                                                                                                                                                                                                                                                                                                                                                          

  Hospital Santiago Apostol \[[@R13]\]                                               25                                                                                                               O/C            Y               Y                                Y                                MMC+CPT-11, 5-FU                                     40-43                        30-90                        

  Subtotal                                                                                                                                                                                            \>25           O/C             Y                                                                 Y                                                    MMC+CPT-11, 5-FU             41.5 (40-43)                 90 (30-120) /30

  Canada, 2                                                                          University of Calgary \[[@R56], [@R66], [@R68], [@R73]\]                                                                                                                                                                                                                                                                         

  Subtotal/Median/Range                                                              375                                                                                                              O              12-15 mg                                         400 mg/m^2^                                                                           41.5 (40-42)                 60                           

  Maisonneuve-Rosemont Hospital, University of Montreal \[[@R14], [@R38], [@R53]\]                                                                                                                                                                                                                                                                                                                                    

  Subtotal/Median/Range                                                              \>40                                                                                                             O              30-50 mg/m^2^   30-50 mg/m^2^ + 50-100 mg/m^2^   360-460 mg/m^2^                  L-OHP (360-460 mg/m^2^) + CPT-11 (100-200 mg/m^2^)   41.5 (41-42.5) /43 (42-43)   90 (60-120) /30 or 60        

  Subtotal                                                                                                                                                                                            \>415          O               12-15 mg /30-50 mg/m^2^          30-50 mg/m^2^ + 50-100 mg/m^2^   360-460 mg/m^2^                                      L-OHP + CPT-11               41.5 (41-42.5) /43 (42-43)   60 or 90 (60-120) /30 or 60

  Greece, 2                                                                          Metaxa Cancer Memorial Hospital \[[@R29], [@R71]\]                                                                                                                                                                                                                                                                               

  Subtotal/Median/Range                                                              ?                                                                                                                O/C            Y                                                Y                                                                                     40-43                        30-120                       

  Didimotichon General Hospital \[[@R13]\]                                           25                                                                                                               O/C            Y               Y                                Y                                MMC+CPT-11, 5-FU                                     40-43                        30-90                        

  Subtotal                                                                                                                                                                                            \>25           O/C             Y                                Y                                Y                                                    MMC+CPT-11, 5-FU             41.5 (40-43)                 30-90

  Australia, 1                                                                       St. George Hospital \[[@R15], [@R26], [@R29], [@R34], [@R41], [@R45], [@R64], [@R72], [@R81], [@R90], [@R91]\]                                                                                                                                                                                                                   

  Subtotal                                                                                                                                                                                            \>618          O               10-12.5 mg/m2                                                     350 mg/m^2^                                                                       42                           90 or 30
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\                   Major Institutions                                                         No. patients   Mode   HIPEC-MMC alone    HIPEC-MMC+DDP                HIPEC-L-OHP alone   HIPEC-other        Temperature\       Duration\
  /No. Institutions                                                                                                                                                                                                  (°C)               (min)
  -------------------------- -------------------------------------------------------------------------- -------------- ------ ------------------ ---------------------------- ------------------- ------------------ ------------------ -----------
  China, 1                   Zhongnan Hospital of Wuhan University \[[@R39]\]                                                                                                                                                           

  Subtotal                                                                                              62             O                         MMC (30 mg) + DDP (120 mg)                                          43.0±0.5           90

  Norway, 1                  Norwegian Radium Hospital \[[@R103]\]                                                                                                                                                                      

  Subtotal                                                                                              109            O/C    35 mg/m2                                                                               41.4 (39.5-42.1)   90

  Denmark, 1                 Aarhus University Hospital \[[@R60], [@R75]\]                                                                                                                                                              

  Subtotal                                                                                              53             O      35 mg/m2                                                                               41-42.5            90

  Germany, 1                 University of Wuerzburg Medical Centre \[[@R15], [@R29], [@R72]\]                                                                                                                                          

  Subtotal                                                                                              \>11           O      10-20 mg/m2                                     Y                                      42 /40-43          90 /30

  Israel. 1                  Tel Aviv Medical Center \[[@R13]\]                                                                                                                                                                         

  Subtotal                                                                                              25             O/C    Y                  Y                            Y                   MMC+CPT-11, 5-FU   40-43              30-90

  Japan, 1                   Shizuoka Cancer Centre \[[@R13]\]                                                                                                                                                                          

  Subtotal                                                                                              25             O/C    Y                  Y                            Y                   MMC+CPT-11, 5-FU   40-43              30-90

  Mexico, 1                  Instituto Jalisciense de Cancerologia \[[@R29], [@R72]\]                                                                                                                                                   

  Subtotal                                                                                              ?              O/C    Y                                               Y                                      40-43              30-120

  Serbia and Montenegro, 1   First Surgical University Hospital, Clinical Center of Serbia \[[@R61]\]                                                                                                                                   

  Subtotal                                                                                              18             C      10 or 12.5 mg/m2                                                                       42                 120
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

###### Summary of HIEPC-related procedures in different PC institutions or countries (published researches)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country\            Major Institutions                                             No. patients   Mode        HIPEC-MMC alone    HIPEC-MMC+DDP                    HIPEC-L-OHP alone   HIPEC-other         Temperature\               Duration\
  /No. Institutions                                                                                                                                                                                         (°C)                       (min)
  ------------------- -------------------------------------------------------------- -------------- ----------- ------------------ -------------------------------- ------------------- ------------------- -------------------------- -----------------
  Serbia, 1           Institute for Oncology and Radiology of Serbia \[[@R70]\]                                                                                                                                                        

  Subtotal                                                                           61             C                                                               410 mg/m2                               41                         30-60

  Singapore, 1        National Cancer Centre Singapore \[[@R79], [@R81]\]                                                                                                                                                              

  Subtotal                                                                           63             C           Y                                                                                           42                         60

  Sweden, 1           Akademiska Sjukhuset, Uppsala University Hospital \[[@R83]\]                                                                                                                                                     

  Subtotal                                                                           38             O                                                               460 mg/m2                               42-44                      30

  Total               73                                                             ≈6,500         O\          n = 64\            n = 24\                          n = 43\             MMC+CPT-11, 5-FU\   41.5 (40-43) /43 (40-43)   90 (60-90) / 60
                                                                                                    (n = 63)\   30-50 mg/m2\       30-50 mg/m^2^ + 50-100 mg/m^2^   460 mg/m2\          L-OHP + CPT-11\                                
                                                                                                    C\          10-12.5 mg/m^2^\                                    360-460 mg/m^2^     MMC + CPT-11                                   
                                                                                                    (n = 51)    35 mg/m^2^\                                                                                                            
                                                                                                                10-20 mg/m^2^                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan

### Patients characteristics {#s2_1_3}

In this meta-analysis, the median complete cytoreduction (CC0-1) rate was 72.2% (range, 32.4% - 100%), including 4 studies with 100% CC0 \[[@R28], [@R35], [@R36], [@R40]\], 7 studies with 50% - 99% CC0 \[[@R14], [@R15], [@R26], [@R29], [@R34], [@R37], [@R99]\], and 4 studies with \<50% CC0 \[[@R12], [@R13], [@R38], [@R39]\]. Major clinico-pathologic characteristics of the 6,857 CRC PC patients (sample size ranging from 11 to 660) in 61 non-controlled studies are listed by Table [6](#T6){ref-type="table"}-[10](#T10){ref-type="table"}.

### HIPEC characteristics {#s2_1_4}

Major technical features of HIPEC procedures in each institution are summarized in Table [11](#T11){ref-type="table"}-[19](#T19){ref-type="table"}. HIPEC was performed using only open technique in 22 institutions and only closed techniques 10 institutions, with 41 institutions used both open and closed techniques. The commonly used chemotherapy agents were mitomycin C (MMC) alone (*n* = 63, dosage of 30-50 mg/m^2^ in 88% of institutions, median temperature 41.5°C, ranging from 40 - 43°C, and median duration 90 min, ranging from 60 - 90 min), oxaliplatin (L-OHP) alone (*n* = 43, dosage of 460 mg/m^2^ in 60% of institutions, median temperature 43°C, ranging from 40 - 43°C; and median duration 60 min), and a combination of MMC and cisplatin (CDDP) (*n* = 24, dosage of 30-50 mg/m^2^ + 50-100 mg/m^2^ in 33% of institutions).

Primary results for meta-analysis {#s2_2}
---------------------------------

### Meta-analysis outcomes {#s2_2_1}

The summarized HRs for OS in the 15 controlled researches was 2.67 (95% CI, 2.21-3.23, *I*^2^ = 0%, *P* \< 0.00001) (Figure [2a](#F2){ref-type="fig"}), suggesting that CRC PC patients could obtain more benefits from CRS plus HIPEC than traditional therapy, without apparent heterogeneity among the studies (*P* = 0.81, *I*^2^ = 0%).

![Forest plots of 15 studies displaying the results of the meta-analysis on hazard ratios (HR) for overall survival (OS) (**a**); Sensitivity analysis of sample size difference (**b**), published-time difference (**c**), and geographic-distribution difference (**d**).](oncotarget-08-55657-g002){#F2}

Sensitivity analysis of summarized HR and 95% CI showed no difference after choosing random effects model and fixed effects model. In terms of sample size difference, 15 researches were divided into three subgroups (sample size \<50, 50-100, \>100) by a sensitivity study for a stratified meta-analysis. The summarized HR and 95% CI showed no difference, with no between-subgroup heterogeneity (*P* = 0.48, *I*^2^ = 0%) (Figure [2b](#F2){ref-type="fig"}). In a sensitivity analysis, four studies with potential heterogeneity was removed due to small sample size \[[@R34]\] or asymmetrical sample size between two groups \[[@R14], [@R26], [@R40], [@R99]\], but the summary HR was 2.81 (95%CI, 2.28-3.48, *I*^2^ = 0%, *P heterogeneity* = 0.56).

There was no statistically significant heterogeneity of HRs for published-time pertinence (*P* = 0.52) (Figure [2c](#F2){ref-type="fig"}) and geographic-distribution pertinence (*P* = 0.43) (Figure [2d](#F2){ref-type="fig"}).

### Analysis of chemotherapy regimens {#s2_2_2}

Regarding the effect of different chemotherapy regimens in HIPEC procedure on the efficacy on OS or DFS, 15 researches were divided into 3 subgroups: group of MMC based chemotherapy, group of L-OHP based chemotherapy, and group of other regimens. The heterogeneity showed no significant difference (*P* = 0.27, *I*^2^ = 24.1%), which revealed that difference of chemotherapy regimens of HIPEC was not associated with OS and DFS after CRS and HIPEC in this meta-analysis (Figure [3a](#F3){ref-type="fig"}). A further analysis of difference in median year survival rate between group of CRS plus HIPEC and group of traditional treatment was conducted by independent-samples *T* test stratified by MMC and L-OHP subgroups (Figure [3b](#F3){ref-type="fig"} and Figure [3c](#F3){ref-type="fig"}).

![Forest plots of 15 studies evaluating heterogeneity test of chemotherapy regimens difference (MMC based chemotherapy; L-OHP based chemotherapy; others) in HIPEC procedure (**a**); The difference of mean year survival rate between CRS+HIPEC group and traditional group for MMC-basic (Mitomycin C, MMC) HIPEC procedure (**b**), for L-OHP-basic (Oxaliplatin, L-OHP) HIPEC procedure (**c**); Forest plots of 15 studies evaluating heterogeneity test of the proportion of CC0 difference (**d**).](oncotarget-08-55657-g003){#F3}

### MMC-based HIPEC procedure {#s2_2_3}

OS data by MMC-based HIPEC procedure were available in 7 studies with 614 patients \[[@R12], [@R13], [@R15], [@R34], [@R35], [@R37], [@R39]\]. Due to more patients received MMC regimen in studies by Elias et al. \[[@R35]\] (21 patients for MMC regimen, while 6 patients for L-OHP regimen) and Glehen et al. \[[@R13]\] (322 patients for MMC regimen, while 32 patients for L-OHP regimen and 29 patients for others), these two studies were included in MMC subgroup. The stratification analysis showed that OS of patients receiving HIPEC by MMC was significantly improved (HR = 2.88, 95% CI, 2.26-3.68, *I*^2^ = 0%, *P* \< 0.00001) (Figure [3a](#F3){ref-type="fig"}), with 1-, 3-, and 5-year survival rates of 79.5%, 38.8%, and 34%, respectively (Figure [3b](#F3){ref-type="fig"}). In comparison, the corresponding survival rates in the traditional group were 54.9%, 18.3%, and 9.7%, respectively (Figure [3b](#F3){ref-type="fig"}).

### L-OHP-based chemotherapy in HIPEC procedure {#s2_2_4}

Four studies using L-OHP based chemotherapy in HIPEC procedures of 283 patients \[[@R28], [@R36], [@R38], [@R40], [@R99]\]. A statistically significant benefit for OS was revealed in HIPEC group (HR = 2.18, 95% CI, 1.57-3.04, *I*^2^ = 0%, *P* \< 0.00001) (Figure [3a](#F3){ref-type="fig"}), with the 1-, 3-, and 5-year survival rates of 93%, 59%, and 43%, respectively in HIPEC group *vs*. 63%, 25%, and 14%, respectively in traditional group (Figure [3c](#F3){ref-type="fig"}).

### Other chemotherapy regimes in HIPEC procedure {#s2_2_5}

Three trials \[[@R14], [@R26], [@R29]\] were identified as the subgroup of other regimen due to difficulties in identifying them as MMC subgroup or L-OHP subgroup since mixed chemotherapy regimens were used in HIPEC during the whole disease course. A significant survival benefit in HIPEC group *vs*. traditional group (HR = 3.90, 95% CI, 1.73-8.81, *I*^2^ = 0%, *P* \< 0.00001) was demonstrated (Figure [3a](#F3){ref-type="fig"}).

### Publication bias {#s2_2_6}

Publication bias was evaluated with funnel plot analyses, as shown in Figure [4](#F4){ref-type="fig"}, and the funnel plot was symmetric. No apparent publication bias was found in our OS meta-analysis with Begg\'s test (z *continuity corrected* = 0.99, *Pr* \>\|z\|*continuity corrected* = 0.32) (Figure [4a](#F4){ref-type="fig"}), or with Egger\'s test (t = 0.82, *P* \>\|t\|= 0.427, 95%CI of bias: -0.49˜1.1) (Figure [4b](#F4){ref-type="fig"}).

![Funnel plots of this meta-analysis by Begg\'s test (**a**), and by Egger\'s test (**b**).](oncotarget-08-55657-g004){#F4}

Summary of HIPEC-related data {#s2_3}
-----------------------------

In 15 controlled studies and 59 single-arm studies, HIPEC-related outcomes including survival rates, median OS and 95% CI, DFS/RFS, PFS, follow-up time, morbidity, and mortality, are summarized in Table [20](#T20){ref-type="table"}-[25](#T25){ref-type="table"} and Figure [5](#F5){ref-type="fig"}

![The summarized median year survival rates between CRS+HIPEC group and traditional group for 15 controlled studies (**a**); The summarized median year survival rates on 76 HIPEC related studies (**b**).](oncotarget-08-55657-g005){#F5}

###### Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                     1-yr SR (%)           2-yr SR (%)          3-yr SR (%)          4-yr SR (%)         5-yr SR (%)           Mortality\         Morbidity\             Median OS\            OS 95% CI\    PFS(95% CI) (mo)   DFS/RFS\                             Follow-up times\
                                                                                                                                                       Rate (%)           Rate (%)               (mo)                  (mo)                             (95% CI) (mo)                        (range) (mo)
  ------------------------------------------ --------------------- -------------------- -------------------- ------------------- --------------------- ------------------ ---------------------- --------------------- ------------- ------------------ ------------------------------------ ----------------------
  Controlled Studies                                                                                                                                                                                                                                                                         

  Chua TC/ 2009/ Australia \[[@R34]\]        ≈84                   ≈50                  ≈26                  NA                  NA                    NR                 NR                     13                    NR            NR                 NR                                   18 (9-59)

  Chua TC/ 2011/ Australia \[[@R15]\]        92                    NR                   55                   NR                  30                    NR                 NR                     38                    30.2 - 45.2   NR                 17 (1-216)\                          17 (1-126)
                                                                                                                                                                                                                                                        (two groups)                         

  Chua TC/ 2013/ Australia \[[@R26]\]        NR                    NR                   NR                   NR                  41                    NR                 NR                     38                    21.1 - 54.9   NR                 33 (22.4-43.8)\                      22 (5-88)
                                                                                                                                                                                                                                                        (RFS)                                

  Elias D/ 2001/ France \[[@R35]\]           NR                    ≈70                  ≈53                  ≈53                 ≈44                   8.1                Overall: 54.6          ≈54                   NR            NR                 ≈26\                                 51.7 (8.1-89.3)
                                                                                                                                                                                                                                                        2-,3-,5-yr 54.7%, 39.4% and 18.4%\   
                                                                                                                                                                                                                                                        (two groups)                         

  Elias D/ 2007/ France \[[@R36]\]           ≈96                   ≈78                  ≈63                  ≈54                 54                    0                  4                      NA                    NR            NR                 NR                                   113 (70-188)

  Elias D/ 2009/ France \[[@R28]\]           NR                    81                   NR                   NR                  51                    NR                 NR                     62.7                  NR            NR                 NR                                   95.7 *vs*. 63

  Elias D/ 2010/ France \[[@R14]\]           NR                    NR                   40                   NR                  25.5                  NR                 NR                     31                    NR            NR                 ≈9\                                  NR
                                                                                                                                                                                                                                                        1-,3-,5-yr\                          
                                                                                                                                                                                                                                                        47%, 15% and 10%\                    
                                                                                                                                                                                                                                                        (two groups)                         

  Esquivel J/ 2014/ America \[[@R29]\]       NR                    NR                   66                   NR                  58                    NR                 NR                     41                    38.0-46.3     NR                 NR                                   25 *vs*. 8 (0.1-128)

  Franko J/ 2010/ America \[[@R37]\]         ≈92                   ≈66                  ≈51                  ≈44                 ≈28                   NR                 NR                     34.7                  NR            NR                 NR                                   NR

  Gervais MK/ 2013/ Canada \[[@R38]\]        ≈92                   ≈76                  61                   ≈53                 36                    4                  20                     ≈54                   NR            NR                 ≈8                                   22.8 (2-81)

  Glehen O/ 2004/ France \[[@R13]\]          NR                    NR                   NR                   NR                  NR                    NR                 NR                     21.6/19.2             NR            NR                 NR                                   53 (5-192)

  Goéré D/ 2015/ France \[[@R99]\]           ≈90                   ≈72                  52                   ≈40                 ≈32                   5.8                29.5                   ≈35                   NR            NR                 NR                                   60 (47-74)

  Huang CQ/ 2014/ China \[[@R39]\]           63.6                  20.0                 16.0                 NR                  NR                    0                  28.6                   13.7                  10.0-16.5     NR                 NR                                   41.5 (11.5-70.9)

  Passot G/ 2014/ France \[[@R40]\]          NR                    NR                   NR                   NR                  NR                    NR                 NR                     36                    NR            NR                 NR                                   NR

  Verwaal VJ/ 2003/ Netherlands \[[@R12]\]   ≈66                   ≈42                  ≈32                  NR                  NR                    8                  19                     22.4                  NR            NR                 NR                                   21.6

  Subtotal of 15 studies\                    84.5 ± 12.6 *vs*.\    61.7 ± 20.3 *vs*.\   46.8 ± 16.2 *vs*.\   48.8 ± 6.4 *vs*.\   40.0 ± 11.5 *vs*.\    4.3 ± 3.7 *vs*.\   19.8 ± 9.2 *vs*.\      34.3 ± 14.8 *vs*.\                                                                          43.8 ± 32.8 *vs*.\
  (Mean ± SD; Median/Range)                  58.1 ± 20.6\          38.8 ± 18.7\         23.6 ± 15.2\         20.4 ± 10.1\        18.1 ± 14.1\          6.2 ± 4.2\         20.5 ± 12.3\           18.8 ± 8.8\                                                                                 29.7 ± 29.3\
                                             91 (63.6-96) *vs*.\   70 (20-81) *vs*.\    52 (16-66) *vs*.\    53 (44-54) *vs*.\   38 (25.5-58) *vs*.\   5 (0-8.1) *vs*.\   19.5 (4-29.5) *vs*.\   35 (13-62.7) *vs*.\                                                                         25 (17-113) *vs*.\
                                             54 (27.5-87)          42 (12-65)           18 (0-47)            22 (14-33)          18 (0-44)             6.3 (0-11.1)       23 (3.1-31.6)          17 (8.5-34)                                                                                 18 (8-63)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy

###### Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                  1-yr SR (%)   2-yr SR (%)   3-yr SR (%)   4-yr SR (%)   5-yr SR (%)   Mortality\   Morbidity\   Median OS\           OS 95% CI\                  PFS(95% CI) (mo)   DFS/RFS\        Follow-up times\
                                                                                                                Rate (%)     Rate (%)     (mo)                 (mo)                                           (95% CI) (mo)   (range) (mo)
  --------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------ ------------ -------------------- --------------------------- ------------------ --------------- ------------------
  HIPEC single arm studies                                                                                                                                                                                                    

  Alzahrani/ 2015/ Australia \[[@R41]\]   ≈84           56            ≈40           ≈26           24            1.2          23.3         28                   NR                          NR                 NR              NR

  Beaujard/ 2000/ France \[[@R42]\]       NR            NR            NR            NR            NR            NR           NR           12                   NR                          NR                 NR              NR

  Bijelic/ 2008/ Australia \[[@R43]\]     ≈94           ≈56           ≈44           ≈23           17            NR           NR           30                   NR                          15                 NR              Mean: 40.8\
                                                                                                                                                                                                                              Median: 29.5

  Braam/ 2014/ Australia \[[@R44]\]       NR            NR            NR            NR            6             NR           NR           14.9                 NR                          NR                 11.4            26.2

  Cao/ 2009/ Australia \[[@R45]\]         83.6          65.4          51.4          32.1          32.1          NR           NR           37.0                 1-72                        NR                 NR              19 (1-72)

  Cavaliere/ 2006/ Italy \[[@R46]\]       NR            NR            25.8          NR            NR            3.3          22.5         19                   NR                          NR                 16              16

  Ceelen/ 2014/ Belgium \[[@R47]\]        ≈75 (NNT)\    ≈57 (NNT)\    ≈39 (NNT)\    ≈32 (NNT)\    ≈25 (NNT)\    NR           NR           27 (included APP)\   20.8-33.2 (included APP)\   NR                 NR              18
                                          ≈75 (NCA)\    ≈47 (NCA)\    ≈30 (NCA)\    ≈19 (NCA)\    ≈13 (NCA)                               24 (Right colon)\    10.3-37.7 (Right colon)\                                       
                                          ≈96 (NCB)     ≈89 (NCB)     ≈71 (NCB)     NA (NCB)                                              27 (Left colon)\     22.8-31.2 (Left colon)\                                        
                                                                                                                                          35 (Rectal)\         4.9-65 (Rectum)\                                               
                                                                                                                                          25 (NNT)\            19.1-30.9 (NNT)\                                               
                                                                                                                                          22 (NCA)\            12.9-31.1 (NCA)\                                               
                                                                                                                                          39 (NCB)\            17.6-60.4 (NCB)\                                               
                                                                                                                                          30 (AC)\             20.7-39.3 (AC)\                                                
                                                                                                                                          22 (NAC)             14.2-29.8 (NAC)                                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy

###### Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                1-yr SR (%)   2-yr SR (%)   3-yr SR (%)   4-yr SR (%)   5-yr SR (%)   Mortality\   Morbidity\   Median OS\                                              OS 95% CI\   PFS(95% CI) (mo)   DFS/RFS\                                                Follow-up times\
                                                                                                              Rate (%)     Rate (%)     (mo)                                                    (mo)                            (95% CI) (mo)                                           (range) (mo)
  ------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------ ------------ ------------------------------------------------------- ------------ ------------------ ------------------------------------------------------- ------------------------
  HIPEC single arm studies                                                                                                                                                                                                                                                              

  Desantis/ 2014/ France \[[@R48]\]     ≈88           ≈72           60.3          ≈47           37            1 (all)      12.5 (all)   45.9                                                    NR           NR                 16.8\                                                   NR
                                                                                                                                                                                                                                1-,3-,5-yr 61.3%, 30.4% and 22.8%                       

  Elias/ 2004/ France \[[@R49]\]        83            74            65            NR            NR            8.3          41.6         NR                                                      NR           NR                 18\                                                     27.4 (18.3-49.6)
                                                                                                                                                                                                                                1-,2-,3-yr 61%, 50% and 50%                             

  Elias/ 2014/ France \[[@R50]\]        91.4          ≈74           54            ≈47           36.5          4.2          17           ≈41                                                     NR           NR                 NR                                                      62.4 (55.6-77.6)

  Evers/ 2011/ Netherlands \[[@R51]\]   NR            NR            NR            NR            36            NR           NR           49.2 *vs*. 41.3\                                        NR           NR                 36.9 *vs*. 32.5\                                        22 (1 week -- 97 mo)
                                                                                                                                        (Ovarian metastases *vs*. without ovarian metastases)                                   (Ovarian metastases *vs*. without ovarian metastases)   

  Faron / 2016/ France \[[@R100]\]      NR            NR            NR            NR            42            4.6          47           41                                                      32-50        NR                 17.7 (12-19)\                                           48.5 (41.0-56.3)
                                                                                                                                                                                                                                5-yr: 14%                                               

  Franko/ 2008/ America \[[@R52]\]      ≈79 (MVR)\    ≈46 (MVR)\    ≈31 (MVR)\    ≈16 (MVR)\    0 (MVR)\      1.4          60           20.2 (MVR)\                                             NR           NR                 NR                                                      NR
                                        ≈12 (NVR)     ≈30 (NVR)     ≈30 (NVR)     ≈30 (NVR)     ≈15 (NVR)                               14.3 (NVR)                                                                                                                                      

  Frøysnes/ 2016/ Norway \[[@R103]\]    ≈93           ≈78           65            ≈45           36            0            15.1         47                                                      42-52        NR                 10 (7-12)                                               45 (35-55)

  Glehen/ 2003/ France \[[@R53]\]       NR            NR            NR            NR            NR            1.8 (all)    28.6 (all)   17.5                                                    4.4-53.6     NR                 NR                                                      18.1 (4.4-56) (all)

  Glehen/ 2004/ France \[[@R16]\]       55            32            NR            NR            11            4            23           12.8                                                    NR           NR                 NR                                                      59.5 (2-148)

  Glehen/ 2010/ France \[[@R54]\]       ≈80           ≈56           41            ≈33           26            4.1 (all)    33.6 (all)   30                                                      NR           NR                 1-,3-,5-yr 77%, 49% and 37%                             45.3 (20.3-90.9) (all)

  Gomes / 2005/ America \[[@R55]\]      ≈60           ≈30           ≈20           ≈20           0             NR           NR           20                                                      NR           NR                 NR                                                      15.7 (1-51)

  Gusani/ 2008/ America \[[@R56]\]      ≈74           ≈49           ≈49           ≈39           NR            0            29.8 (all)   ≈23.6                                                   NR           NR                 NR                                                      35.9 (19.0-57.7) (all)

  Hamilton/ 2011/ Canada \[[@R57]\]     ≈79           ≈62           38            ≈34           34            NR           NR           27                                                      0-87         NR                 9 (0-87)\                                               28 (0-119) (all)
                                                                                                                                                                                                                                3-,5-yr 34%,26%                                         

  Hompes/ 2012/ Belgium \[[@R58]\]      97.9          88.7          ≈84           NA            NA            0            52.1         NA                                                      NA           NR                 19.8 (12--upper limit not defined) (RFS)                22.7 (3.2-55.7)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy

###### Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                               1-yr SR (%)    2-yr SR (%)    3-yr SR (%)    4-yr SR (%)    5-yr SR (%)   Mortality\     Morbidity\     Median OS\      OS 95% CI\           PFS(95% CI) (mo)   DFS/RFS\                            Follow-up times\
                                                                                                                                 Rate (%)       Rate (%)       (mo)            (mo)                                    (95% CI) (mo)                       (range) (mo)
  ---------------------------------------------------- -------------- -------------- -------------- -------------- ------------- -------------- -------------- --------------- -------------------- ------------------ ----------------------------------- -------------------------
  HIPEC single arm studies                                                                                                                                                                                                                                 

  Hompes/ 2014/ Belgium \[[@R59]\]                     ≈91 (L-OHP)\   ≈68 (L-OHP)\   ≈53 (L-OHP)\   ≈45 (L-OHP)\   NA            0              41.1           37.1 (L-OHP)\   22.4-52.8 (L-OHP)\   NR                 12.2 (7.2-undefined) (L-OHP)\       33.6 (L-OHP)\
                                                       ≈88 (MMC)      ≈59 (MMC)      ≈42 (MMC)      ≈33 (MMC)                                                  26.5 (MMC)      16.9-64.8 (MMC)                         13.8(7.0-25.8) (MMC) (RFS)          61.2 (MMC)

  Iversen/ 2013/ Denmark \[[@R60]\]                    ≈97            60             47             38             38            2.9            32.4           ≈31             NR                   NR                 NR                                  16.0 (0.9--71.3)

  Kecmanovic/ 2005/ Serbia and Montenegro \[[@R61]\]   ≈85            ≈85            ≈85            ≈85            NA            0              44.4           15              1-57                 NR                 NR                                  21 (1-56)

  Kianmanesh/ 2007/ France \[[@R62]\]                  ≈95            72             ≈57            44             44            2.3            39             38.4            32.8-43.9            NR                 NR                                  NR

  Klaver/ 2011/ Netherlands \[[@R63]\]                 71             ≈56            ≈43            ≈35            ≈18           NR             NR             28              3-100                NR                 NR                                  NR

  Klaver/ 2012/ Netherlands \[[@R64]\]                 83             ≈52            ≈26            ≈26            NA            0              33.3           35              20.0-49.9            NR                 12 (7.7-16.3)                       10.5 (1-52)

  Kuijpers/ 2013/ Netherlands \[[@R65]\]               ≈84            ≈62            46             ≈37            31            3\             34\            33              28-38                15 (13--17)        NR                                  41 (35-46) included PMP
                                                                                                                                 included PMP   included PMP                                                                                               

  Kuijpers/ 2014/ Netherlands \[[@R66]\]               ≈87            ≈62            45             ≈37            ≈32           0              30             30              19-41                15 (14-16)         NR                                  47 (43-51)

  Lanuke/ 2009/ Canada \[[@R67]\]                      ≈85            ≈58            ≈46            NA             NA            4 (all)        39 (all)       26              1-48                 NR                 8 (1-31)                            12 (1-48)

  Levine/ 2014/ America \[[@R68]\]                     ≈69            ≈38            ≈27            ≈19            ≈17           3.8 (all)      42 (all)       ≈19             NR                   NR                 NR                                  NR

  Maillet/ 2016/ France \[[@R101]\]                    NR             NR             58             NR             34            4              NR             43.3            NR                   12.4               NR                                  NR

  McConnell/ 2013/ Canada \[[@R69]\]                   NR             NR             NR             NR             NR            0              36.9           NR              NR                   NR                 NR                                  NR

  Nikolic/ 2014/ Serbia \[[@R70]\]                     78.6           58.7           ≈53            ≈50            ≈42           NR             NR             51              \>22                 NR                 23 (\>16)\                          22 (1-83)
                                                                                                                                                                                                                       1-,2-,6-yr 68.3%, 46.7% and 38.1%   

  Passot/ 2012/ France \[[@R21]\]                      77             51             NR             NR             33            NR             NR             36.2            NR                   NR                 NR                                  58.5 (1-183)

  Passot/ 2016/ France \[[@R104]\]                     ≈83            ≈65            ≈51            ≈38            31            NR             30             36              NR                   NR                 11                                  NR

  Pilati/ 2003/ Italy \[[@R71]\]                       ≈68            31             NR             NR             NR            0              35             18              NR                   13                 NR                                  14.5

  Prada-Villaverde/ 2014/ Spaini \[[@R72]\]            ≈85            ≈63            ≈45            ≈38            ≈35           NR             NR             31.4            NR                   NR                 NR                                  NR

  Quenet/ 2011/ France \[[@R73]\]                      ≈92            ≈72            ≈36            ≈47            ≈44           4.1            47.2           41              32--60               NR                 15.7 (12--18) (RFS)                 48.5 (41.0--56.3)

  Rivard/ 2014/ Canada \[[@R74]\]                      ≈88 (Colon)\   ≈68 (Colon)\   ≈46 (Colon)\   NA             NA            NR             NR             ≈31 (Colon)\    NR                   NR                 10.9\                               30.3 (2-88)
                                                       ≈80 (Rectal)   ≈24 (Rectal)   ≈30 (Rectal)                                                              ≈18 (Rectal)                                            3-yr, 15%                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy

###### Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                   1-yr SR (%)    2-yr SR (%)    3-yr SR (%)     4-yr SR (%)    5-yr SR (%)   Mortality\     Morbidity\    Median OS\      OS 95% CI\   PFS(95% CI) (mo)   DFS/RFS\                          Follow-up times\
                                                                                                                      Rate (%)       Rate (%)      (mo)            (mo)                            (95% CI) (mo)                     (range) (mo)
  ---------------------------------------- -------------- -------------- --------------- -------------- ------------- -------------- ------------- --------------- ------------ ------------------ --------------------------------- ----------------------
  HIPEC single arm studies                                                                                                                                                                                                           

  Rodt/ 2013/ Denmark \[[@R75]\]           ≈52            ≈36            ≈12             0              0             0              9.4 (all)     12.7            4.0-21.4     NR                 NR                                13 (1-44)

  Shen/ 2004/ America \[[@R20]\]           NR             NR             25              NR             17            12             30            16              10-26        7 (3-31)           NR                                15

  Shen/ 2008/ America \[[@R76]\]           91             ≈60            48              ≈32            26            5.5            41.8          34              23-45        NR                 NR                                86

  Simkens/ 2015/ Netherlands \[[@R102]\]   NR             NR             42              NR             NR            3              24.8          27              18.8-35.3    NR                 1-yr: 35%                         22.9 (0.4-75.3)

  Swellengrebel/ 2009/ Netherlands\        NR             NR             NR              NR             NR            NR             NR            25.6            20.9-29.4    13.6 (11.2-16.4)   NR                                NR
  \[[@R77]\]                                                                                                                                                                                                                         

  Tabrizian/ 2014/ America \[[@R78]\]      74.0           ≈47            89.4            NA             NA            NR             NR            NR              NR           NR                 12.4±1.8 (RFS)\                   15.7±1.2
                                                                                                                                                                                                   1-,3-yr,\                         
                                                                                                                                                                                                   46.9%, 73.9%                      

  Teo/ 2013/ Singapore \[[@R79]\]          ≈87            ≈58            ≈36             ≈18            ≈18           0              56 (all)      ≈28             NR           NR                 ≈10                               21 (13.9-31.3) (all)

  Teo/ 2014/ Singapore \[[@R80]\]          83.7           ≈53            38.2            19.1           19.1          0              40            27.1            15.3-39.1    NR                 9.4 (5.5-18.7)\                   24.7 (0.6-81.8)
                                                                                                                                                                                                   1-,3-,5-yr, 43.8%, 22.3%, 22.3%   

  Ung/ 2013/ Australia \[[@R81]\]          ≈84 (Colon)    ≈63 (Colon)    ≈53 (Colon)     ≈37 (Colon)    33 (Colon)    NR             NR            37.1 (Colon)\   NR           NR                 12.6 (Colon)\                     23.3 (1-156) (all)
                                                                                                                                                   29.6 (Rectal)                                   19.0 (Rectal)                     

  Vaira/ 2010/ Italy\                      100 (L-OHP)\   ≈60 (L-OHP)\   ≈18 (L-OHP)\    ≈18 (L-OHP)\   NA (L-OHP)\   2.5            55            24.6 (L-OHP)\   NR           NR                 NR                                NR
  \[[@R82]\]                               ≈61 (MMC)      ≈17 (MMC)      ≈9 (MMC)        ≈4 (MMC)       0 (MMC)                                    16.6 (MMC)                                                                        

  van Leeuwen / 2008/ Sweden \[[@R83]\]    ≈82            ≈65            NA              NA             NA            \>1 (all)      56.3 (all)    NA              NA           NR                 2-yr, 33.5% (all)                 13 (2-37) (all)

  van Oudheusden/ 2014/ Netherlands\       ≈86            ≈70            ≈43             ≈30            ≈22           1.8            22.1          36.1            NR           NR                 NR                                16.2 (0.13-90)
  \[[@R84]\]                                                                                                                                                                                                                         

  van Oudheusden / 2015/ Netherlands\      ≈87            ≈68            44              ≈38            ≈27           NR             13.5          35.1            NR           NR                 NR                                12.7(0.10-90.2)
  \[[@R85]\]                                                                                                                                                                                                                         

  Varban/ 2009/ America \[[@R86]\]         ≈63            36.8           ≈25             17.4           ≈16           7.7            40.1          15.8            13.5-20.2    NR                 NR                                13.4

  Verwaal/ 2005/ Netherlands \[[@R19]\]    75             NR             28              NR             19            NR             NR            21.8            19.0-25.5    NR                 NR                                46

  Votanopoulos/ 2013/ America \[[@R87]\]   ≈63 (Colon)\   ≈31 (Colon)\   25.1 (Colon)\   NR             NR            5.7 (Colon)\   57 (Colon)\   17.3 (Colon)\   NR           NR                 NR                                88.1 (Colon)\
                                           ≈83 (Rectal)   ≈36 (Rectal)   28.2 (Rectal)                                0 (Rectal)     46 (Rectal)   14.6 (Rectal)                                                                     40.1 (Rectal)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy

###### Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/ Years/ Country                  1-yr SR (%)     2-yr SR (%)     3-yr SR (%)     4-yr SR (%)                5-yr SR (%)     Mortality\   Morbidity\     Median OS\     OS 95% CI\   PFS(95% CI) (mo)   DFS/RFS\          Follow-up times\
                                                                                                                                     Rate (%)     Rate (%)       (mo)           (mo)                            (95% CI) (mo)     (range) (mo)
  --------------------------------------- --------------- --------------- --------------- -------------------------- --------------- ------------ -------------- -------------- ------------ ------------------ ----------------- ------------------
  HIPEC single arm studies                                                                                                                                                                                                        

  Winer/ 2014/ America\                   53              22              22              ≈13                        ≈13             6.7          22.2           12.2           7.5-17.2     9.3 (3.3-17.8)\    NR                52.8 (12.5-138)
  \[[@R88]\]                                                                                                                                                                                 1-,3-yr,\                            
                                                                                                                                                                                             47%, 16%                             

  Witkamp/ 2001/ Netherlands \[[@R89]\]   NR              45              23              NR                         NR              3            38             NR             NR           NR                 11 (3-29) (RFS)   38 (26-52)

  Yan/ 2006/ Australia\                   72              64              NR              NR                         NR              0            NR             29             2-39         NR                 NR                12 (2-39)
  \[[@R90]\]                                                                                                                                                                                                                      

  Yan/ 2008/ Australia\                   79              67              39              NR                         NR              NR           NR             29             1-56         NR                 NR                14 (1-56)
  \[[@R91]\]                                                                                                                                                                                                                      

  Zanon/ 2006/ Italy \[[@R92]\]           ≈75             ≈60             ≈28             NR                         NR              4            24             30.3           17.0-52.2    17.3 (5.72-28.9)   NR                NR

  Total of 76 studies\                    79.7 ± 14.5;\   56.5 ± 17.3;\   42.3 ± 17.1;\   33.8 ± 15.4; 34.5 (0-85)   27.5 ± 14.1;\   2.8 ± 2.9\   33.0 ± 13.4\   29.2 ± 11.3\                13.1 ± 3.2\        15.9 ± 7.7\       33.1 ± 22.5
  (Mean±SD; Median/Range)                 83 (12-100)     60 (17-89)      42 (9-89.4)                                31 (0-58)       2.5 (0-12)   32.9 (4-60)    29 (12-62.7)                13.6 (7-17.3)      12.6 (8-36.9)     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy

Adverse events {#s2_4}
--------------

In controlled studies, the mean (± SD) mortality and morbidity rates were 4.3% (± 3.7%) and 19.8% (± 9.2%) in HIPEC groups, 6.2% (± 4.2%) and 20.5% (± 12.3%) in traditional groups, respectively (Table [20-25](#T25){ref-type="table"}). No significant difference in mortality (*P* = 0.423) or morbidity (*P* = 0.815) was detected between HIPEC group and traditional group by *T* test. In the integrated HIPEC-related data of 76 studies, mean mortality and morbidity was 2.8% (± 2.9%) and 33.0 (± 13.4%), respectively.

DISCUSSION {#s3}
==========

Due to the tumor biologic characteristics of colorectal cancer, about 10-13% patients have already progressed to PC when CRC is diagnosed \[[@R3], [@R7]\], which has a poor prognosis. In order to improve the efficacy, a comprehensive treatment strategy with combination of CRS plus HIPEC had been developed. With wide application of this treatment, CRS plus HIPEC has been proved capable to achieve better survival in selected patients with PC from colorectal cancer.

This meta-analysis of 15 controlled studies demonstrated that CRS+HIPEC comprehensive therapeutic strategy could bring significant survival benefit for selected CRC PC patients than traditional treatment of palliative surgery alone or systemic chemotherapy (HR = 2.67, 95% CI 2.21-3.23, *P* \< 0.00001). In addition, the summarizing analysis of these 76 studies showed that the median OS was about 29 months in HIPEC group, which is significant longer compared with median OS of 17.9 months for CRC PC patients receiving contemporary chemotherapy reported by Kerscher et al (*n* = 2,406) \[[@R7]\]. These results provide further supporting evidence that CRS+HIPEC as the principal comprehensive treatment can bring more survival benefit to selected patients with CRC PC than traditional therapy.

The different regimens used in chemotherapy may be one potential confounding factor for survival outcomes. In order to investigate the influence of chemotherapy regimens on postoperative survival, a stratification analysis between MMC based regimens and L-OHP based regimens was conducted. The results of heterogeneity showed no significant difference (*P* = 0.50). These results are inconsistent with the reports by Elias et al \[[@R14]\], which showed that OS advantage for L-OHP regimens over non-L-OHP regimens (32 *vs*. 25 months, *P* = 0.02). However, L-OHP used in HIPEC was not an independent prognostic factor for survival in the study of Elias and colleagues. A multi-center retrospective controlled study reported by Prada-Villaverde et al. \[[@R72]\] showed that of 539 patients undergoing CRS plus HIPEC, L-OHP based HIPEC and MMC based HIPEC achieved similar median OS (31.4 *vs*. 32.7 months, *P* = 0.925). Similarly, the study of Hompes et al. \[[@R59]\] yielded the same conclusion that there was not obvious benefit in OS for HIPEC with L-OHP (37.1 months) or MMC (26.5 months) (*P* = 0.45). Although different chemotherapy regimens in HIPEC may have an effect on stability and reliability of this meta-analysis, the result of heterogeneity analysis was in accordance with above studies. As a result, both MMC and L-OHP were the feasible chemotherapy drugs in HIPEC for CRC PC patients to achieve similar efficacy.

Moreover, there are also some doubts that different chemotherapy in intravenous or postoperative intraperitoneal therapy regimens, even targeted therapy, had interference on the survival outcomes in meta-analysis. The doubts were removed by the report of Kerscher et al \[[@R7]\]. In 2,406 CRC patients of no-PC and PC, the survival outcomes for contemporary chemotherapy regimens (oxaliplatin or irinotecan) were compared with 5-FU regimens. For the CRC patients (without PC), survival outcomes for contemporary regimens were increased over 5-FU regimens (5-year survival rate 71.6% *vs*. 63.3%, *P* = 0.001). On the contrary, for patients with PC from CRC, the survival of L-OHP or irinotecan agent was similar to 5-FU regimens (*P* \> 0.05), regardless of synchronous PC (2-year survival rate 31.1% *vs*. 19.1%, *P* = 0.092, and 5-year survival rate 20.8% *vs.* 5.8%, *P* = 0.081) or metachronous PC (2-year survival rate 71.5% *vs*. 58.5%, *P* = 0.329, and 5-year survival rate 28.1% *vs*. 24.4%, *P* = 0.411).

There were a few statistical flaws in this meta-analysis. For example, only one RCT \[[@R12]\] was included. It may be due to the difficulty of performing RCT. Therefore, we had to select meticulously current studies of best evidence level besides the only RCT. However, this meta-analysis showed acceptable outcomes of low heterogeneity and sensitivity. Regrettably, a patient-level (based on single patient data) meta-analysis as the gold standard for meta-analysis was not performed because of the difficulty in obtaining vast data from each database or institution. In addition to meta-analysis, this report provided a summary of 76 clinical studies published until today about CRS and HIPEC, which can get a review of published studies. In order to get the best evidence level results, more RCTs and prospective, multicenter, large-scale clinical trials need to be performed in future studies.

Observing available data from 6 controlled studies (a total of 470patients) \[[@R12], [@R35], [@R36], [@R38], [@R39], [@R99]\], mortality or morbidity were found similar in both groups of HIPEC and traditional surgery, which was 4.3% *vs*. 5.0% and 19.8% *vs*. 19.5%, respectively. The summarized HIPEC-related mortality and morbidity in 48 articles (the total number of patients, *n* = 4,809) \[[@R12], [@R16], [@R20], [@R35], [@R36], [@R38], [@R39], [@R46], [@R48]-[@R50], [@R52]-[@R54], [@R56], [@R58]-[@R62], [@R64]-[@R69], [@R71], [@R73], [@R75], [@R76], [@R79], [@R80], [@R82]-[@R90], [@R92], [@R100]-[@R104]\] were 2.8% (SD, ± 2.9%; range, 0-12%) and 33.0% (SD, ± 13.4%; range, 4-60%), respectively. Some large-sample retrospective studies and population-based analysis found a series of approximate results that the range of mortality was 2%-5.6% and morbidity was 25%-34% \[[@R93]-[@R97]\]. Furthermore, a systematic review of morbidity and mortality for CRS+HIPEC by Chua et al. \[[@R98]\] showed that the mortality and morbidity range from 0.9% to 5.8% and 12% to 52%, respectively. Though evidence proved that safety for CRS+HIPEC was acceptable, a meta-analysis on mortality and mortality for CRS+HIPEC may be able to provide more convincing results on the mortality and morbidity.

With the summary of 76 studies, it is found that although HIPEC is now widely accepted and performed in most institutions, details of performing HIPEC varies among different institutions. As we noted, there are several mainly different techniques concerning HIPEC including 1) "open" or "closed" technique, 2) using MMC and/or L-OHP, 3) mono-chemotherapy or combination of chemotherapy regimens, 4) temperature and duration of HIPEC. These can be further studied in future studies.

In conclusion, this meta-analysis showed that CRS+HIPEC comprehensive therapeutic strategy was associated with improvement of OS in CRC PC patients, and the results of the meta-analysis were proved of good reliability by low heterogeneous and robust sensitivity. Meanwhile, CRS and HIPEC can be performed with acceptable safety according to summary results of all 76 studies.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

The following databases were systematically searched up to July 31, 2016 including PubMed, Science Citation Index, EMBASE, and MEDLINE. The Cochrane Central Register of Controlled Trials, the National Institutes of Health trial registry, and conference proceeding articles from major oncologic and gastrointestinal cancer meetings were also sought for published results. The key words included "colon", "rectum", "colorectal", "cancer", "peritoneal carcinomatosis", "hyperthermic intraperitoneal chemotherapy", and synonyms and related terms for these words. The MeSH terms included "colon cancer", "rectal cancer", "colorectal cancer", "peritoneal carcinomatosis", "hyperthermic chemotherapy", "hyperthermic intraperitoneal chemotherapy", "HIPEC", "intraperitoneal chemohyperthermia", and "IPCH". The combined application of "key words terms" and "MeSH terms" were conducted to improve the efficiency and accuracy of literature search.

Selection criteria {#s4_2}
------------------

For inclusion in the meta-analysis and summarized HIPEC-related data analysis, a study had to fulfill the following criteria: (1) According to the North-England evidence-based guidelines \[[@R105], [@R106]\], excluded from IV levels evidence of literatures were included; (2) All patients were diagnosed CRC PC; (3) For assessing CRS+HIPEC±SC/EPIC, the intervening measure group was CRS+HIPEC±SC/EPIC, while the control group was traditional therapy of surgery and/or SC; For systematic review of CRS+HIPEC to treat CRC PC, HIPEC-related literatures involving clinical efficacy evaluation were included; (4) The key outcome measures should be included in literatures, such as OS, disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), year survival rate, morbidity and mortality \[[@R107]\], multivariate analysis, follow-up times; (5) English language; (6) To reduce the effect of publication bias, both fully published articles and abstracts were eligible for inclusion.

Exclusion criteria: (1) Animal studies, pathological research, imageology research, pharmacokinetics research, quality of life assessment, literature review, commentary, letter, book, etc; (2) Duplicate publication or overlapping data (chose the largest and latest sample size); (3) The sample size is less than 10; (4) Multiple cancer; (5) Unresectable liver metastases or others distant metastasis; (6) missing rate of follow-up \> 5%.

Data extraction {#s4_3}
---------------

Three authors analyzed data from a meta-analysis of 15 controlled researches of CRS plus HIPEC group *vs*. surgery and/or SC group and a summarized analysis of 76 researches of HIPEC group. The following data were extracted from each article: (1) Major clinico-pathologic characteristics and detail HIPEC regimens; (2) Survival and advent events. All relevant text, tables, and figures were reviewed for data extraction. For equivocal literatures or discrepancies between two independently assessed reviewers, these were resolved by discussion and consensus with a third author.

Statistical methods {#s4_4}
-------------------

All meta-analysis were performed using Review Manager 5. Overall survival (OS) or disease-free survival (DFS) in all studies were extracted from original literature. If not achieved accurate data in original text, hazard ratios (HRs) for time-to-event outcomes with 95% confidence intervals (95% CI) in two groups were estimated by Tierney\'s methods \[[@R108]\]. The heterogeneity in the meta-analysis was evaluated by *I*^2^ statistics \[[@R109]\] and *T* test \[[@R110]\] was calculated for each result in summarizing analysis of all HIPEC-related data from the included 76 articles. If *I*^2^ \>50%, it was defined as the unacceptable heterogeneity. If *I*^2^ \<50%, fixed effect model was used to get pooled HR and 95% CI; otherwise, random effects model was used if moderate heterogeneity. For a sensitivity analysis, we investigated the different research features of eligible trials, which included statistical methods, methodological quality, sample sizes, and clinical factors on HIPEC-related effect, after that, summarizing each subgroup data in term of Mental-Haenszel stratification analysis. According to Egger\'s test \[[@R111]\] and Begg\'s test \[[@R112]\], publication bias was considered to be inevitable when *P* \< 0.10. The funnel plot analyses using 'STATA: Data Analysis and Statistical Software version 12.0', was to observe the results of meta-analysis whether any publication bias.
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